[
  {
    "date": "2023-06-30",
    "symbol": "MEOBF",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2023-06-30",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MESO",
    "entityregistrantname": "MESOBLAST LTD",
    "entitycentralindexkey": 1345099,
    "currentfiscalyearenddate": "--06-30",
    "security12btitle": "American Depositary Shares, each representing five Ordinary Shares",
    "securityexchangename": "NASDAQ",
    "entityfilenumber": "001-37626",
    "entityincorporationstatecountrycode": "C3",
    "entityaddressaddressline1": "Level 38",
    "entityaddressaddressline2": "55 Collins Street",
    "entityaddresscityortown": "Melbourne",
    "entityaddresspostalzipcode": 3000,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentregistrationstatement": "false",
    "documentshellcompanyreport": "false",
    "icfrauditorattestationflag": "true",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "contactpersonnelname": "Silviu Itescu",
    "cityareacode": "+61 (3)",
    "localphonenumber": "9639 6036",
    "contactpersonnelfaxnumber": "+61 (3) 9639 6030",
    "entityaddresscountry": "AU",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Accelerated Filer",
    "entitycommonstocksharesoutstanding": 814204825,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entityinteractivedatacurrent": "Yes",
    "auditorfirmid": 1379,
    "auditorname": "PricewaterhouseCoopers",
    "auditorlocation": "Melbourne, Australia",
    "documentfinstmterrorcorrectionflag": "false",
    "revenue": 7501000,
    "researchanddevelopmentexpense": 27189000,
    "manufacturingcommercialization": 27733000,
    "managementandadministrationexpense": 25374000,
    "fairvalueremeasurementofcontingentconsideration": -8771000,
    "fairvalueremeasurementofwarrantliability": 2205000,
    "otheroperatingincomeexpense": 4250000,
    "financecosts": 20122000,
    "profitlossbeforetax": -82101000,
    "incometaxexpensecontinuingoperations": -212000,
    "profitlossattributabletoownersofparent": -81889000,
    "basicearningslosspersharefromcontinuingoperations": -0.1108,
    "dilutedearningslosspersharefromcontinuingoperations": -0.1108,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": 573000,
    "reclassificationadjustmentsonfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincomenetoftax": 1000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": -574000,
    "comprehensiveincomeattributabletoownersofparent": -82463000,
    "equity": 1249123000,
    "profitloss": -81889000,
    "othercomprehensiveincome": -1000,
    "comprehensiveincome": -1000,
    "increasedecreasethroughothercontributionsbyowners": 83814000,
    "increasedecreasethroughtransactionswithowners": 83814000,
    "taxcreditedordebitedtoequity": 212000,
    "increasedecreasethroughsharebasedpaymenttransactions": 3655000,
    "changesinequity": 3443000,
    "cashandcashequivalents": 71318000,
    "tradeandothercurrentreceivables": 6998000,
    "currentprepayments": 3342000,
    "currentassets": 81658000,
    "propertyplantandequipment": 1357000,
    "rightofuseassets": 5134000,
    "noncurrentfinancialassetsatfairvaluethroughothercomprehensiveincome": 1757000,
    "othernoncurrentassets": 2326000,
    "intangibleassetsandgoodwill": 577183000,
    "noncurrentassets": 587757000,
    "assets": 669415000,
    "tradeandothercurrentpayables": 20145000,
    "currentprovisions": 6399000,
    "currentportionoflongtermborrowings": 5952000,
    "currentleaseliabilities": 4060000,
    "warrantliability": 5426000,
    "currentliabilities": 41982000,
    "noncurrentprovisions": 16612000,
    "longtermborrowings": 102811000,
    "noncurrentleaseliabilities": 3672000,
    "deferredconsiderationnoncurrent": 2500000,
    "noncurrentliabilities": 125595000,
    "liabilities": 167577000,
    "netassetsliabilities": 501838000,
    "issuedcapital": 1249123000,
    "otherreserves": 73520000,
    "retainedearnings": -820805000,
    "commercializationrevenuereceived": 7480000,
    "governmentgrantsandtaxincentivesreceived": 1118000,
    "paymentstosuppliersandemployeesinclusiveofgoodsandservicestax": 72683000,
    "interestreceivedclassifiedasoperatingactivities": 796000,
    "incometaxespaidrefundclassifiedasoperatingactivities": -20000,
    "cashflowsfromusedinoperatingactivities": -63269000,
    "investmentinfixedassets": -264000,
    "receiptsfrominvestmentinsublease": 120000,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 50000,
    "cashflowsfromusedininvestingactivities": -194000,
    "paymentsoftransactioncostsfromborrowings": 574000,
    "interestandothercostsoffinancepaidclassifiedasfinancingactivities": 6014000,
    "proceedsfromissuingshares": 88635000,
    "paymentsforshareissuecosts": 4889000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 2656000,
    "cashflowsfromusedinfinancingactivities": 74502000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 11039000,
    "effectofexchangeratechangesoncashandcashequivalents": -168000,
    "disclosureofsignificantchangesincurrentreportingperiodexplanatorytextblock": "Significant changes in the current reporting period",
    "disclosureofdetailedinformationaboutlossbeforeincometaxexplanatorytextblock": "Loss before income tax",
    "disclosureoffinancialassetsandfinancialliabilitiesexplanatorytextblock": "Financial assets and liabilities",
    "disclosureofsignificantestimatesjudgmentsanderrorsexplanatorytextblock": "Significant estimates, judgments and errors",
    "disclosureofcapitalmanagementexplanatorytextblock": "Capital managementThe Group’s objective when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders. See Note 5(a) for the cash reserves of the Group as at the end of the financial reporting period.",
    "disclosureofcontingentassetsandliabilitiesexplanatorytextblock": "Contingent assets and liabilities",
    "disclosureoflegalproceedingsexplanatorytextblock": "Legal proceedings",
    "disclosureofsummaryofsignificantaccountingpoliciesexplanatory": "Summary of significant accounting policies",
    "descriptionofaccountingpolicyforbasisofpreparationexplanatorypolicytextblock": "Basis of preparation",
    "descriptionofaccountingpolicyforchangeinaccountingpoliciesexplanatorypolicytextblock": "a.    Change in accounting policiesThere were no new accounting policies adopted by the Group in the year ended June 30, 2023.",
    "descriptionofaccountingpolicyforroundingofamountsexplanatorypolicytextblock": "aa.    Rounding of amountsOur company is of a kind referred to in ASIC Corporations (Rounding in Financial/Directors’ Reports) Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to the ‘rounding off’ of amounts in the financial report. Unless mentioned otherwise, amounts within this report have been rounded off in accordance with that Legislative Instrument to the nearest thousand dollars, or in certain cases, to the nearest dollar.",
    "disclosureofdetailedinformationaboutincometaxexplanatorytabletextblock": "Year Ended June 30, (in U.S. dollars, in thousands)202320222021(b)Income tax (benefit)/expense   Current tax   Current tax— — — Total current tax (benefit)/expense— — —    Deferred tax   (Increase)/decrease in deferred tax assets38 (8,317)(1,158)(Decrease)/increase in deferred tax liabilities(250)8,078 339 Total deferred tax (benefit)/expense(212)(239)(819)Income tax (benefit)/expense(212)(239)(819)",
    "disclosureofamountsthatwouldberecognizeddirectlyinequityexplanatorytabletextblock": "Year Ended June 30, (in U.S. dollars, in thousands)202320222021(d)Amounts recognized directly in equityAggregate current and deferred tax arising in the reporting period and not recognized in net loss or other comprehensive income but debited/credited to equity   Current tax recorded in equity— — — Deferred tax recorded in equity212 239 91 212 239 91",
    "disclosureofdeferredtaxassetsnotbroughttoaccountexplanatorytabletextblock": "Year Ended June 30,  (in U.S. dollars, in thousands)202320222021(e)Deferred tax assets not brought to account    Unused tax losses    Potential tax benefit at local tax rates125,728 111,283 77,738  Other temporary differences    Potential tax benefit at local tax rates12,318 11,046 7,424  Other tax credits    Potential tax benefit at local tax rates3,220 3,220 3,220   141,266 125,549 88,382",
    "disclosureofdetailedinformationaboutnetdebtexplanatorytabletextblock": "(iii)    Net debt reconciliationAs of June 30,(in U.S. dollars, in thousands)20232022Cash and cash equivalents71,318 60,447 Borrowings(108,763)(96,634)Lease liabilities(7,732)(10,271)Warrant liability(5,426)(2,185)Net Debt(1)(50,603)(48,643)Cash and cash equivalents71,318 60,447 Gross debt - fixed interest rates(116,495)(106,905)Gross debt - variable interest rates— — Warrant liability(5,426)(2,185)Net Debt(1)(50,603)(48,643)(1)Net debt amount includes leases and borrowing arrangements",
    "disclosureofdetailedinformationaboutvaluationprocessesofcontingentconsiderationatfairvalueexplanatorytabletextblock": "As of June 30,The fair value of contingent consideration (in U.S. dollars, in thousands)20232022Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets16,606 17,827 Fair value of royalty payments from commercialization of the intellectual property acquired593 5,457 17,199 23,284",
    "disclosureofdetailedinformationaboutwarrantliabilityexplanatorytabletextblock": "(vi)    Warrant liability (in U.S. dollars, in thousands)As of June 30,Warrant liability20232022Opening balance2,185 — Warrants fair value at grant date - November 19, 2021— 8,081 Warrants fair value at grant date - December 22, 20221,036 — Remeasurement of warrant liability2,205 (5,896)Closing Balance5,426 2,185",
    "disclosureofdetailedinformationaboutfairvalueofwarrantsexplanatorytabletextblock": "The following assumptions were based on observable market conditions that existed as of June 30, 2023 and 2022.",
    "disclosureofleaseliabilitiesexplanatorytabletextblock": "Lease liabilitiesAs of June 30,20232022Current4,060 3,186 Non-current3,672 7,085 Lease liabilities included in the balance sheet7,732 10,271",
    "disclosureofcarryingvalueofinprocessresearchanddevelopmentacquiredbyproductexplanatorytabletextblock": "Carrying value of in-process research and development acquired by product",
    "disclosureofdeferredconsiderationexplanatorytabletextblock": "As of June 30,(in U.S. dollars, in thousands)20232022Opening balance(1)2,500 2,500 Amount recognized as revenue during the period— — Balance as of the end of the period2,500 2,500 (1)The $2.5 million milestone payment received in December 2019 from Grünenthal was considered constrained and resulted in deferred consideration as of June 30, 2023.",
    "disclosureofborrowingsderivingpriceriskexplanatorytabletextblock": "The exposure of the Group’s borrowing to price rate changes are as follows:As of Jun 30, 2023 As of June 30, 2022 (in U.S. dollars, in thousands, except percent data)Total% of total borrowingsTotal% of total borrowingsFinancial liabilities    Current borrowings    Borrowings – NovaQuest336 0 %372 0 %Non-current borrowings    Borrowings – NovaQuest55,739 51 %47,898 50 %56,075 51 %48,270 50 %",
    "disclosureofsummaryofparententityfinancialinformationexplanatorytabletextblock": "The individual financial statements for the parent entity show the following aggregate amounts:",
    "maximumamountincashoutflowsfromoperatingactivities": 63300000,
    "numberofwarrantsgrantedtopurchaseamericandepositaryshares": 2224669,
    "parvaluepershare": 3.7,
    "commercializationrevenue": 7501000,
    "clinicaltrialrelatedresearchanddevelopment": 8771000,
    "manufacturingproductionanddevelopment": 25468000,
    "wagesandsalaries": 17197000,
    "definedcontributionsuperannuationexpenses": 384000,
    "decreaseincreasethroughtaxonsharebasedpaymenttransactions": 3655000,
    "employeebenefitsexpense": 21236000,
    "depreciationpropertyplantandequipment": 953000,
    "depreciationrightofuseassets": 1661000,
    "intellectualpropertyamortization": 1493000,
    "amortisationexpense": 4107000,
    "overheadsandadministrationexpenses": 10104000,
    "consultancyexpenses": 3922000,
    "legalpatentandotherprofessionalfees": 3695000,
    "intellectualpropertyexpenses": 2993000,
    "othermanagementandadministrationexpenses": 20714000,
    "lossgainonremeasurementofcontingentconsideration": -8771000,
    "lossgainonremeasurementofwarrantliability": 2205000,
    "rdtaxincentiveincome": 3506000,
    "interestrevenuecalculatedusingeffectiveinterestmethod": 831000,
    "foreignexchangegainslosses": -163000,
    "derecognitionofrightofuseasset": 76000,
    "financecostsgainsonremeasurementofborrowingarrangements": -678000,
    "interestexpense": 19444000,
    "taxincentiveincomecurrent": 1200000,
    "taxexpenseincomeatapplicabletaxrate": -24630000,
    "sharebasedcompensationexpense": 1089000,
    "researchanddevelopmenttaxconcessions": -730000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 501000,
    "incometaxcontingentconsideration": -2631000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 695000,
    "currenttaxexpenseincome": -25706000,
    "adjustmentsforcurrenttaxofpriorperiod": 274000,
    "taxeffectofforeigntaxrates": 8537000,
    "incometaxbenefitnotrecognized": 16683000,
    "taxrateeffectfromchangeintaxrate": 0.3,
    "applicabletaxrate": 0.17,
    "increasedecreaseindeferredtaxassets": 38000,
    "increasedecreaseindeferredtaxliabilities": 250000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -212000,
    "currenttaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": -1716000,
    "deferredtaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": 839000,
    "currentanddeferredtaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": -877000,
    "deferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": 212000,
    "currentanddeferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": 212000,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 125728000,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": 12318000,
    "othertaxcreditsforwhichnodeferredtaxassetrecognised": 3220000,
    "deferredtaxassetsnotbroughttoaccount": 141266000,
    "taxeffectoftaxlosses": 553000000,
    "deferredtaxassets": 44500000,
    "deferredtaxassetexpirationperiod": "P9Y",
    "tradeandotherreceivables": 6998000,
    "financialassetsatfairvaluethroughothercomprehensiveincome": 1757000,
    "othernoncurrentfinancialassets": 2326000,
    "financialassets": 1757000,
    "borrowings": 108763000,
    "contingentconsiderations": 17199000,
    "financialliabilities": 22625000,
    "balanceswithbanks": 70920000,
    "depositsatcall": 398000,
    "interestbearingdepositsatcallheldassecurity": 400000,
    "tradereceivables": 2276000,
    "researchanddevelopmenttaxincentivecreditreceivable": 2363000,
    "foreignwithholdingtaxrecoverable": 471000,
    "receivablefromtaxcredits": 1473000,
    "netinvestmentinfinancelease": 195000,
    "currentinterestreceivable": 18000,
    "receivablesfromtaxesotherthanincometax": 202000,
    "clinicaltrialresearchanddevelopmentexpenditure": 950000,
    "prepaidinsuranceandsubscriptions": 2025000,
    "otherprepayments": 367000,
    "prepayments": 3342000,
    "tradereceivablessettlementperiod": "P60D",
    "borrowingsterm": "P8Y",
    "financecostsgainslossonremeasurementofborrowingarrangements": -1600000,
    "financecostsgainslossonremeasurementduetoadditionalwarrantsissued": 1000000,
    "financecostsgainslossonadjustmentofcarryingamountonfinancialliability": 600000,
    "minimumunrestrictedcashbalance": 35000000,
    "percentageofassetsmeasuredatfairvalue": 1,
    "percentageofliabilitiesmeasuredatfairvalue": 1,
    "warrantsfairvalueatissuedate": 1036000,
    "gainlossonremeasurementofwarrantliability": 2200000,
    "noncurrentfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincome": 1757000,
    "tradeandotherpayables": 20145000,
    "securedbankloansreceived": 81919000,
    "borrowingcostsrecognisedasexpense": 8740000,
    "borrowingcostscapitalised": 35584000,
    "shorttermborrowings": 336000,
    "leaseliabilities": 7732000,
    "netdebt": 50603000,
    "liabilitiesarisingfromfinancingactivities": 121921000,
    "cashflowsadjustmentsondebt": 5926000,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": 3170000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": 9096000,
    "increasedecreaseinliabilitiesarisingfromfinancingactivities": 20135000,
    "remeasurementadjustmentsondebt": 358000,
    "remeasurementadjustmentsonwarrants": -2205000,
    "remeasurementadjustmentsondebtandwarrants": -1847000,
    "increasedecreaseinborrowingliabilitiesclassifiedasfinancingactivities": -18413000,
    "increasedecreaseinleaseliabilitiesarisingfromfinancingactivities": -738000,
    "otherchangesondebtandleases": -19151000,
    "issuanceofwarrantswarrantliability": -1036000,
    "issuanceofwarrants": -1036000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromleases": 107000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromfinancingactivities": 107000,
    "effectofforeignexchangeadjustmentsonliabilitiesarisingfromfinancingactivitiesandcashandcashequivalents": -61000,
    "financialassetsatfairvalue": 1757000,
    "financialliabilitiesatfairvalue": 22625000,
    "contingentconsiderationprovision": 17199000,
    "contingentconsiderationprovisionamountused": -2686000,
    "gainlossonremeasurementofcontingentconsiderationprovision": 8800000,
    "percentageofweightedaverageofsignificantunobservableinputsliabilities": -0.125,
    "percentageofreasonablypossibleincreasedecreaseinunobservableinputliabilities": 0.005,
    "percentageofreasonablypossibleincreasedecreaseinfairvaluemeasurementduetochangeinunobservableinputliabilities": 0.0001,
    "cashorstockpayableatfairvalueliabilities": 16606000,
    "royaltypaymentsatfairvalueliabilities": 593000,
    "remeasurementofwarrantliability": 2205000,
    "warrantspricepershare": 3.91,
    "descriptionofoptionlifeshareoptionsgranted": 6.5,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.8126,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0401,
    "fairvalueperwarrant": 2.3103,
    "fairvalueofwarrants": 5426212,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P3Y",
    "interestexpenseonleaseliabilities": 500000,
    "cashoutflowforleases": 3200000,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 1100000,
    "noncancellabletermofleaseandnonleasecomponents": "P2Y",
    "minimumfinancialcommitmentofleasecomponent": 3000000,
    "minimumfinancialcommitmentreductionamountonleasecomponent": 1100000,
    "goodwill": 2100000,
    "numberofacquisition": 2,
    "numberofreportableoperatingsegment": 1,
    "inprocessresearchanddevelopmentrecognized": 61900000,
    "posttaxdiscountrates": 0.138,
    "expectedpatentexpiry": "P9Y",
    "currentprovisionsforaccruedannualleave": 1100000,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P7Y",
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 171000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": -104000,
    "derecognitionofrightofuseassets": 649000,
    "rightofuseassetsrevaluedassetsatcost": 526000,
    "rightofuseassetsincreasedecreaseinrevaluationsurplus": -15000,
    "additionsreversalotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 23000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": 1000,
    "amortisationintangibleassetsotherthangoodwill": 38000,
    "provisions": 17199000,
    "deferredtaxassetsattributabletotemporarydifferencesfromtaxlosses": 76020000,
    "deferredtaxassetsattributabletoothertemporarydifferences": 11972000,
    "deferredtaxliabilitiesattributabletotemporarydifferencesfromintangibleassets": 87992000,
    "deferredtaxliabilities": 87992000,
    "deferredtaxliabilityasset": -76020000,
    "netmovementinregulatorydeferralaccountbalancesrelatedtoprofitorlossandnetmovementinrelateddeferredtax": 4179000,
    "netmovementinregulatorydeferralaccountbalancesrelatedtodirectlytoequity": 212000,
    "deferredconsideration": 2500000,
    "numberofsharesissued": 814204825,
    "treasurysharespurchased": 542903,
    "numberofsharesoutstanding": 813661922,
    "ordinarysharespurchasedvalue": 1249123000,
    "sharesavailableforissuanceunderissuanceplan": 163750274,
    "sharesissuedinplacementsvalue": 89141000,
    "transactioncostsarisingonshareissue": 5327000,
    "contributionsofequityduringperiod": 163750274,
    "contributionsofvalueforequityduringperiod": 83814000,
    "sharesheldintrust": 542903,
    "increasedecreasethroughtransfersandotherchangesequity": -212000,
    "gainslossesonexchangedifferencesontranslationnetoftax": -573000,
    "weightedaverageshareprice2019": 1.85,
    "adjustmentsfordepreciationandamortisationexpense": 4107000,
    "adjustmentsforunrealisedforeignexchangelossesgains": 62000,
    "adjustmentsforfinanceincomecost": -20122000,
    "fairvalueremeasurementofcontingentconsiderationaftertax": -8771000,
    "remeasurementofwarrantliabilities": 2205000,
    "adjustmentsforsharebasedpayments": 3655000,
    "adjustmentsfordeferredtaxexpense": -212000,
    "decreasethroughderecognitionfinancialassets": 76000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -118000,
    "adjustmentsforincreasedecreaseinprepayments": 1650000,
    "adjustmentsforincreasedecreaseintradecreditorsandaccruals": -398000,
    "increasedecreaseindeferredtaxliabilityasset": 2388000,
    "adjustmentsforprovisions": -1218000,
    "percentageofcashheld": 0.67,
    "effectonprofitfromchangeintaxrate": 0.1,
    "percentageofforecastnetsales": 0.2,
    "noninterestbearingfinancialliabilitiesmaturityperiod": "P6M",
    "fundsinvestedpercentage": 0.0179,
    "increaseininterestratepercentage": 0.0197,
    "decreaseininterestratepercentage": 0.0161,
    "fundsinvestedwhichderivesinterestrevenue": 40569000,
    "increaseininterestrateonfundsinvestedwhichderivesinterestrevenue": 73000,
    "decreaseininterestrateonfundsinvestedwhichderivesinterestrevenue": 73000,
    "effectonprofitfromchangeininterestrateincreaseordecrease": 0.1,
    "percentageofpriceratechangesinnoncurrentborrowings": 0.51,
    "percentageofpriceratechangesinborrowings": 0.51,
    "receivablesfromotherparties": 2276000,
    "receivablesfromincometax": 2363000,
    "receivablefromforeignwithholdingtax": 400000,
    "receivablesfrombankdeposits": 18000,
    "valueaddedtaxreceivables": 3000,
    "receivablefromtaxcreditsnoncurrent": 1912000,
    "derivativefinancialliabilitiesundiscountedcashflows": -6668000,
    "grossloancommitments": 108763000,
    "proportionofownershipinterestsheldbynoncontrollinginterests": 1,
    "milestonepayment": 2200000,
    "minimumremainingfinancialcommitmentofnonleasecomponentonexerciseofoptiontoextendnoncancellableterm": 16800000,
    "minimumfinancialcommitmentofleasecomponentonexerciseofoptiontoextendnoncancellableterm": 3000000,
    "minimumfinancialcommitmentreductionamount": 12200000,
    "minimumfinancialcommitmentreductionamountonnonleasecomponent": 11100000,
    "noncancellablepurchasecommitments": 9100000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 2153181,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 11326,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 23935,
    "keymanagementpersonnelcompensationsharebasedpayment": 881342,
    "keymanagementpersonnelcompensation": 3069784,
    "shareoptionsvestingtomaximumintimebasedconditions": 0.3333,
    "periodofvestingrequirementsforsharebasedpaymentarrangement": "P12M",
    "percentageofpremiumattachedwithtimebasedvestingconditionoptions": 0.1,
    "employeeshareoptionplanmaximumnumberofoptionsavailableforissuance": 10000000,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsandloanfunded": "P4Y1M17D",
    "numberoftranchesofshareplangranted": 3,
    "expirytermofoptions": "P7Y",
    "tranchevestingterm": "P1Y",
    "optionexerciseterminconnectionwithcessationofemployment": "P60D",
    "numberofequaltranchesvestondate": 2,
    "numberofequaltranchespriortovesting": 2,
    "weightedaveragesharepriceshareoptionsgranted2019": 1.08,
    "closingsharemarketpriceofordinaryshare": 1.14,
    "exercisepriceofoutstandingshareoptions2019": 2.8,
    "numberofoutstandingshareoptions": 1500000,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 1250000,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 1678979,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 1500000,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 2.39,
    "weightedaveragesharepriceexercisableinsharebasedpaymentarrangement": 2.12,
    "sharepriceatvaluationdate": 0.99,
    "expectedlifeafterfactoring": "P6Y3M18D",
    "auditorsremunerationforauditservices": 669603,
    "auditorsremunerationforotherservices": 180339,
    "auditorsremuneration": 849942,
    "basicearningslosspershare": -0.1108,
    "dilutedearningslosspershare": -0.1108,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententity": -81889000,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -81889000,
    "profitlossattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -81889000,
    "weightedaverageshares": 739039547,
    "adjustedweightedaverageshares": 739039547,
    "reserveofexchangedifferencesontranslation": -261377000,
    "reserveofsharebasedpayments": 86274000,
    "warrantreserve": 12969000,
    "numberofoperatingsegment": 1,
    "numberofclassactionlawsuits": 1,
    "revenuefromperformanceobligationssatisfiedorpartiallysatisfiedinpreviousperiods": 2500000,
    "amountentitledtobereceivedonnonrefundableupfrontpaymentuponreachingproductregulatorymilestone": 25000000,
    "revenuefromroyalties": 400000,
    "regulatorymilestonepaymentreceivable": 1000000,
    "royaltiesreceivableundersalesbasedmilestones": 7100000,
    "annualaggregateturnoveramount": 20000000,
    "percentageofresearchanddevelopmenttoreceiverefundabletaxoffset": 0.085,
    "prelaunchinventoryrecognized": 22400000,
    "tradeandotherreceivablesdueforsettlementterm": "P60D",
    "tradeandotherpayablesmaturityperiod": "P30D"
  },
  {
    "date": "2022-06-30",
    "symbol": "MEOBF",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2022-06-30",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MESO",
    "entityregistrantname": "MESOBLAST LTD",
    "entitycentralindexkey": 1345099,
    "currentfiscalyearenddate": "--06-30",
    "security12btitle": "American Depositary Shares, each representing five Ordinary Shares",
    "securityexchangename": "NASDAQ",
    "entityfilenumber": "001-37626",
    "entityincorporationstatecountrycode": "C3",
    "entityaddressaddressline1": "Level 38",
    "entityaddressaddressline2": "55 Collins Street",
    "entityaddresscityortown": "Melbourne",
    "entityaddresspostalzipcode": 3000,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentregistrationstatement": "false",
    "documentshellcompanyreport": "false",
    "icfrauditorattestationflag": "true",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "contactpersonnelname": "Silviu Itescu",
    "cityareacode": "+61 (3)",
    "localphonenumber": "9639 6036",
    "contactpersonnelfaxnumber": "+61 (3) 9639 6030",
    "entityaddresscountry": "AU",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Large Accelerated Filer",
    "entitycommonstocksharesoutstanding": 650454551,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entityinteractivedatacurrent": "Yes",
    "auditorfirmid": 1379,
    "auditorname": "PricewaterhouseCoopers",
    "auditorlocation": "Melbourne, Australia",
    "revenue": 10214000,
    "researchanddevelopmentexpense": 32815000,
    "manufacturingcommercialization": 30757000,
    "managementandadministrationexpense": 27210000,
    "fairvalueremeasurementofcontingentconsideration": -913000,
    "fairvalueremeasurementofwarrantliability": -5896000,
    "otheroperatingincomeexpense": -539000,
    "financecosts": 17288000,
    "profitlossbeforetax": -91586000,
    "incometaxexpensecontinuingoperations": -239000,
    "profitlossattributabletoownersofparent": -91347000,
    "basicearningslosspersharefromcontinuingoperations": -0.1408,
    "dilutedearningslosspersharefromcontinuingoperations": -0.1408,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": -91000,
    "reclassificationadjustmentsonfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincomenetoftax": 322000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": -231000,
    "comprehensiveincomeattributabletoownersofparent": -91578000,
    "equity": 1165309000,
    "profitloss": -91347000,
    "othercomprehensiveincome": -322000,
    "comprehensiveincome": -322000,
    "increasedecreasethroughothercontributionsbyowners": 1928000,
    "increasedecreasethroughtransactionswithowners": 1928000,
    "taxcreditedordebitedtoequity": 239000,
    "increasedecreasethroughexerciseofoptions": 228000,
    "increasedecreasethroughsharebasedpaymenttransactions": 5536000,
    "changesinequity": 228000,
    "cashandcashequivalents": 60447000,
    "tradeandothercurrentreceivables": 4403000,
    "currentprepayments": 4987000,
    "currentassets": 69837000,
    "propertyplantandequipment": 2045000,
    "rightofuseassets": 7920000,
    "noncurrentfinancialassetsatfairvaluethroughothercomprehensiveincome": 1758000,
    "othernoncurrentassets": 1930000,
    "intangibleassetsandgoodwill": 578652000,
    "noncurrentassets": 592305000,
    "assets": 662142000,
    "tradeandothercurrentpayables": 23079000,
    "currentprovisions": 17906000,
    "currentportionoflongtermborrowings": 5017000,
    "currentleaseliabilities": 3186000,
    "warrantliability": 2185000,
    "currentliabilities": 51373000,
    "noncurrentprovisions": 12523000,
    "longtermborrowings": 91617000,
    "noncurrentleaseliabilities": 7085000,
    "deferredconsiderationnoncurrent": 2500000,
    "noncurrentliabilities": 113725000,
    "liabilities": 165098000,
    "netassetsliabilities": 497044000,
    "issuedcapital": 1165309000,
    "otherreserves": 70651000,
    "retainedearnings": -738916000,
    "commercializationrevenuereceived": 9980000,
    "governmentgrantsandtaxincentivesreceived": 24000,
    "paymentstosuppliersandemployeesinclusiveofgoodsandservicestax": 75769000,
    "interestreceivedclassifiedasoperatingactivities": 7000,
    "incometaxespaidrefundclassifiedasoperatingactivities": 24000,
    "cashflowsfromusedinoperatingactivities": -65782000,
    "investmentinfixedassets": -157000,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 75000,
    "cashflowsfromusedininvestingactivities": -232000,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 51919000,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 55458000,
    "paymentsoftransactioncostsfromborrowings": 5527000,
    "interestandothercostsoffinancepaidclassifiedasfinancingactivities": 6084000,
    "proceedsfromissuingshares": 209000,
    "proceedsfromissuingwarrants": 8081000,
    "paymentsforshareissuecosts": 222000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 2788000,
    "cashflowsfromusedinfinancingactivities": -9870000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -75884000,
    "effectofexchangeratechangesoncashandcashequivalents": -550000,
    "maximumamountincashoutflowsfromoperatingactivities": 65800000,
    "percentageofreductionincashoutflowsfromoperatingactivities": 0.35,
    "borrowings": 96634000,
    "borrowingsinterestrate": 0.097,
    "borrowingsmaturity": "July 8, 2026",
    "numberofwarrantsgrantedtopurchaseamericandepositaryshares": 1769669,
    "parvaluepershare": 7.26,
    "commercializationrevenue": 9039000,
    "milestonerevenue": 1172000,
    "revenuefrominterest": 3000,
    "clinicaltrialrelatedresearchanddevelopment": 10483000,
    "manufacturingproductionanddevelopment": 28884000,
    "wagesandsalaries": 18997000,
    "definedcontributionsuperannuationexpenses": 402000,
    "decreaseincreasethroughtaxonsharebasedpaymenttransactions": 5536000,
    "employeebenefitsexpense": 24935000,
    "depreciationpropertyplantandequipment": 1144000,
    "depreciationrightofuseassets": 1717000,
    "intellectualpropertyamortization": 1519000,
    "amortisationexpense": 4380000,
    "overheadsandadministrationexpenses": 10157000,
    "consultancyexpenses": 3751000,
    "legalpatentandotherprofessionalfees": 5571000,
    "intellectualpropertyexpenses": 2621000,
    "othermanagementandadministrationexpenses": 22100000,
    "lossgainonremeasurementofcontingentconsideration": 913000,
    "lossgainonremeasurementofwarrantliability": 5896000,
    "foreignexchangegainslosses": -536000,
    "foreignwithholdingtaxespaid": 3000,
    "financecostsgainsonremeasurementofborrowingarrangements": -382000,
    "interestexpense": 16906000,
    "taxexpenseincomeatapplicabletaxrate": -27476000,
    "sharebasedcompensationexpense": 1588000,
    "researchanddevelopmenttaxconcessions": -869000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 2000,
    "incometaxcontingentconsideration": -274000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": -2036000,
    "currenttaxexpenseincome": -28908000,
    "adjustmentsforcurrenttaxofpriorperiod": -923000,
    "taxeffectofforeigntaxrates": 8407000,
    "incometaxbenefitnotrecognized": 21185000,
    "taxeffectonincreasedecreaseindeferredtaxassets": -8326000,
    "increasedecreaseincurrenttaxliability": -8326000,
    "taxrateeffectfromchangeintaxrate": 0.3,
    "applicabletaxrate": 0.17,
    "increasedecreaseindeferredtaxassets": -8317000,
    "increasedecreaseindeferredtaxliabilities": -8078000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -239000,
    "currenttaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": -142000,
    "deferredtaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": 715000,
    "currentanddeferredtaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": 573000,
    "deferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": 239000000,
    "currentanddeferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": 239000000,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 111283000000,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": 11046000000,
    "othertaxcreditsforwhichnodeferredtaxassetrecognised": 3220000000,
    "deferredtaxassetsnotbroughttoaccount": 125549000000,
    "taxeffectoftaxlosses": 477800000,
    "deferredtaxassets": 44400000,
    "deferredtaxassetexpirationperiod": "P10Y",
    "tradeandotherreceivables": 4403000,
    "financialassetsatfairvaluethroughothercomprehensiveincome": 1758000,
    "othernoncurrentfinancialassets": 1930000,
    "financialassets": 1758000,
    "contingentconsiderations": 23284000,
    "financialliabilities": 25469000,
    "balanceswithbanks": 60034000,
    "depositsatcall": 413000,
    "interestbearingdepositsatcallheldassecurity": 400000,
    "tradereceivables": 2224000,
    "foreignwithholdingtaxrecoverable": 471000,
    "receivablefromtaxcredits": 1473000,
    "receivablesfromtaxesotherthanincometax": 235000,
    "clinicaltrialresearchanddevelopmentexpenditure": 1313000,
    "prepaidinsuranceandsubscriptions": 2420000,
    "otherprepayments": 1254000,
    "prepayments": 4987000,
    "tradereceivablessettlementperiod": "P60D",
    "gainslossesonfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincomenetoftax": -300000,
    "financecostsgainslossonremeasurementofborrowingarrangements": -900000,
    "borrowingsterm": "P8Y",
    "minimumunrestrictedcashbalance": 35000000,
    "percentageofassetsmeasuredatfairvalue": 1,
    "warrantsfairvalueatissuedate": 2200000,
    "gainlossonremeasurementofwarrantliability": 5900000,
    "noncurrentfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincome": 1758000,
    "tradeandotherpayables": 23079000,
    "securedbankloansreceived": 81919000,
    "borrowingcostsrecognisedasexpense": 8247000,
    "borrowingcostscapitalised": 22962000,
    "shorttermborrowings": 372000,
    "leaseliabilities": 10271000,
    "netdebt": 48643000,
    "cashflowsadjustmentsondebt": 14512000,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": 3427000,
    "increasedecreaseinwarrantliabilitiesarisingfromfinancingactivities": -8081000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": 9858000,
    "increasedecreaseinliabilitiesarisingfromfinancingactivities": -66026000,
    "remeasurementadjustmentsondebt": -382000,
    "remeasurementadjustmentsonwarrants": 5896000,
    "remeasurementadjustmentsondebtandwarrants": 5514000,
    "otherchangesondebtandleases": -17748000,
    "increasedecreaseinborrowingliabilitiesclassifiedasfinancingactivities": -16519000,
    "increasedecreaseinleaseliabilitiesarisingfromfinancingactivities": -1229000,
    "acquisitionofleases": -1463000,
    "increasedecreaseinacquisitionofleaseliabilitiesarisingfromfinancingactivities": -1463000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromleases": 244000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromfinancingactivities": 244000,
    "effectofforeignexchangeadjustmentsonliabilitiesarisingfromfinancingactivitiesandcashandcashequivalents": -306000,
    "liabilitiesarisingfromfinancingactivities": -109090000,
    "financialassetsatfairvalue": 1758000,
    "financialliabilitiesatfairvalue": 25469000,
    "contingentconsiderationprovision": 23284000,
    "contingentconsiderationprovisionamountused": 1212000,
    "gainlossonremeasurementofcontingentconsiderationprovision": 900000,
    "percentageofweightedaverageofsignificantunobservableinputsliabilities": -0.125,
    "descriptionofinterrelationshipsbetweenunobservableinputsandofhowtheymightmagnifyormitigateeffectofchangesinunobservableinputsonfairvaluemeasurementliabilities": "Year ended June 30, 2022: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.2%. Year ended June 30, 2021: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.3%.",
    "cashorstockpayableatfairvalueliabilities": 17827000,
    "royaltypaymentsatfairvalueliabilities": 5457000,
    "remeasurementofwarrantliability": -5896000,
    "warrantspricepershare": 2.22,
    "descriptionofoptionlifeshareoptionsgranted": 6.5,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.8322,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0308,
    "fairvalueofwarrants": 2185476,
    "informationaboutlesseesexposurearisingfromextensionoptionsandterminationoptions": "As of June 30, 2022, the anticipated future contractual cash flows relating to the lease component of the Lonza agreement are $4.1 million on an undiscounted basis, as included within lease liabilities in Note 10(c). The anticipated future contractual cash flows exclude cashflows beyond the initial non-cancellable lease term as it is not reasonably certain the Group will extend the agreement.",
    "minimumfinancialcommitmentofleasecomponent": 4100000,
    "noncancellabletermofleaseandnonleasecomponents": "P3Y",
    "depreciationmethodpropertyplantandequipment": "Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over the estimated useful lives.",
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P3Y",
    "cashoutflowforleases": 3400000,
    "interestexpenseonleaseliabilities": 600000,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 3200000,
    "amortisationmethodintangibleassetsotherthangoodwill": "7 – 16 years",
    "goodwill": 2100000,
    "numberofreportableoperatingsegment": 1,
    "inprocessresearchanddevelopmentrecognized": 387000000,
    "posttaxdiscountrates": 0.138,
    "expectedpatentexpiry": "P11Y",
    "currentprovisionsforaccruedannualleave": 1000000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 143000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 54000,
    "additionstorightofuseassets": 1464000,
    "rightofuseassetsrevaluedassetsatcost": 97000,
    "rightofuseassetsincreasedecreaseinrevaluationsurplus": -165000,
    "additionsreversalotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": -450000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": 74000,
    "amortisationintangibleassetsotherthangoodwill": 64000,
    "provisions": 23284000,
    "deferredtaxassetsattributabletotemporarydifferencesfromtaxlosses": 80411000,
    "deferredtaxassetsattributabletoothertemporarydifferences": 7831000,
    "deferredtaxliabilitiesattributabletotemporarydifferencesfromintangibleassets": 88242000,
    "deferredtaxliabilities": 88242000,
    "deferredtaxliabilityasset": -80411000,
    "netmovementinregulatorydeferralaccountbalancesrelatedtoprofitorlossandnetmovementinrelateddeferredtax": -8742000,
    "netmovementinregulatorydeferralaccountbalancesrelatedtodirectlytoequity": 247000,
    "deferredconsideration": 2500000,
    "numberofsharesissued": 650454551,
    "treasurysharespurchased": 542903,
    "numberofsharesoutstanding": 649911648,
    "ordinarysharespurchasedvalue": 1165309000,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 229080,
    "sharebasedcompensationforservicesrenderedshares": 1758481,
    "sharebasedcompensationforservicesrendered": 1698000,
    "transactioncostsarisingonshareissue": -21000,
    "contributionsofequityduringperiod": 1758481,
    "contributionsofvalueforequityduringperiod": 1928000,
    "shareoptionsreservetransferredtoequityonexerciseofoptionsvalue": 228000,
    "sharesheldintrust": 542903,
    "increasedecreasethroughtransfersandotherchangesequity": -239000,
    "valueofshareoptionsexercisedinsharebasedpaymentarrangement": -228000,
    "gainslossesonexchangedifferencesontranslationnetoftax": 91000,
    "weightedaverageshareprice2019": 2.21,
    "adjustmentsfordepreciationandamortisationexpense": 4380000,
    "adjustmentsforunrealisedforeignexchangelossesgains": 536000,
    "adjustmentsforfinanceincomecost": -16906000,
    "remeasurementofborrowingarrangementsnet": 382000,
    "fairvalueremeasurementofcontingentconsiderationaftertax": -913000,
    "remeasurementofwarrantliabilities": -5896000,
    "adjustmentsforsharebasedpayments": 5536000,
    "adjustmentsfordeferredtaxexpense": -235000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 140000,
    "adjustmentsforincreasedecreaseinprepayments": 1555000,
    "adjustmentsforincreasedecreaseintradecreditorsandaccruals": 4777000,
    "adjustmentsforprovisions": -1603000,
    "percentageofcashheld": 0.97,
    "changeininterestrateeffectonprofitloss": 0.05,
    "effectonprofitfromchangeintaxrate": 0.1,
    "noninterestbearingfinancialliabilitiesmaturityperiod": "P6M",
    "percentageofforecastnetsales": 0.2,
    "increasenoncurrentborrowing": 200000,
    "decreaseinprofit": 200000,
    "decreasenoncurrentborrowings": 200000,
    "increaseinprofit": 200000,
    "percentageofdecreasenetsales": 0.2,
    "increaseininterestratepercentage": 0.0003,
    "decreaseininterestratepercentage": 0.0003,
    "fundsinvestedpercentage": 0.015,
    "fundsinvestedwhichderivesinterestrevenue": 49383000,
    "increaseininterestrateonfundsinvestedwhichderivesinterestrevenue": 15000,
    "decreaseininterestrateonfundsinvestedwhichderivesinterestrevenue": 15000,
    "effectonprofitfromchangeininterestrateincreaseordecrease": 0.1,
    "percentageofpriceratechangesinnoncurrentborrowings": 0.5,
    "percentageofpriceratechangesinborrowings": 0.5,
    "receivablesfromotherparties": 2382000,
    "receivablesfromincometax": 5000,
    "receivablefromforeignwithholdingtax": 400000,
    "receivablesfrombankdeposits": 254000,
    "valueaddedtaxreceivables": 105000,
    "receivablefromtaxcreditsnoncurrent": 1473000,
    "derivativefinancialliabilitiesundiscountedcashflows": -5628000,
    "grossloancommitments": 96634000,
    "nameofsubsidiary": "Mesoblast, Inc.",
    "countryofincorporationorresidenceofsubsidiary": "USA",
    "proportionofownershipinterestsheldbynoncontrollinginterests": 1,
    "milestonepayment": 2200000,
    "minimumremainingfinancialcommitmentofnonleasecomponentonexerciseofoptiontoextendnoncancellableterm": 12200000,
    "minimumfinancialcommitmentofleasecomponentonexerciseofoptiontoextendnoncancellableterm": 4100000,
    "noncancellablepurchasecommitments": 9400000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 2294897,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 12206,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 31346,
    "keymanagementpersonnelcompensationsharebasedpayment": 391592,
    "keymanagementpersonnelcompensation": 2730041,
    "dateofgrantofsharebasedpaymentarrangement": "In accordance with the Company’s policy, options and loan funded shares are typically issued in three equal tranches. For issues granted prior to July 1, 2015 the length of time from grant date to expiry date was typically 5 years. Grants since July 1, 2015, are issued with a seven year term.",
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met.",
    "percentageofpremiumattachedwithtimebasedvestingconditionoptions": 0.1,
    "employeeshareoptionplanmaximumnumberofoptionsavailableforissuance": 10000000,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 1.82,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsandloanfunded": "P4Y1M28D",
    "numberoftranchesofshareplangranted": 3,
    "expirytermofoptions": "P5Y",
    "tranchevestingterm": "P1Y",
    "optionexerciseterminconnectionwithcessationofemployment": "P60D",
    "optionsconversionratio": 63.978,
    "optionsvestedonacquisitiondate": "2010-12-07",
    "numberofequaltranchesvestondate": 2,
    "numberofequaltranchespriortovesting": 2,
    "weightedaveragesharepriceshareoptionsgranted2019": 1.77,
    "closingsharemarketpriceofordinaryshare": 0.61,
    "sharebasedpaymentsarrangementexpirationdate": "30-Jun-22",
    "exercisepriceofoutstandingshareoptions2019": 2.28,
    "numberofoutstandingshareoptions": 1678979,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 200000,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 1753334,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 1678979,
    "weightedaverageexercisepriceofshareoptionsinsharebasedpaymentarrangementexercisedduringperiodatdateofexercise2019": 1.25,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 2.99,
    "weightedaveragesharepriceexercisableinsharebasedpaymentarrangement": 2.06,
    "valuationdate": "05-May-21",
    "sharepriceatacceptancedate": 1.94,
    "expectedlifeafterfactoring": "P6Y3M18D",
    "auditorsremunerationforauditservices": 745021,
    "auditorsremunerationforotherservices": 67238,
    "auditorsremuneration": 812259,
    "basicearningslosspershare": -0.1408,
    "dilutedearningslosspershare": -0.1408,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententity": -91347000,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -91347000,
    "profitlossattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -91347000,
    "weightedaverageshares": 648899589,
    "adjustedweightedaverageshares": 648899589,
    "reserveofexchangedifferencesontranslation": -227441000,
    "reserveofsharebasedpayments": 82619000,
    "warrantreserve": 12969000,
    "numberofoperatingsegment": 1,
    "revenuefromperformanceobligationssatisfiedorpartiallysatisfiedinpreviousperiods": 2500000,
    "deferredconsiderationmilestoneconsiderationrecognized": 20000000,
    "amountentitledtobereceivedonnonrefundableupfrontpaymentuponreachingproductregulatorymilestone": 25000000,
    "revenuefromroyalties": 300000,
    "milestonerevenueinrelationtopatentlicenseagreement": 1200000,
    "regulatorymilestonepaymentreceivable": 1000000,
    "royaltiesreceivableundersalesbasedmilestones": 8700000,
    "annualaggregateturnoveramount": 20000000,
    "percentageofresearchanddevelopmenttoreceiverefundabletaxoffset": 0.085,
    "prelaunchinventoryrecognized": 28900000,
    "tradeandotherreceivablesdueforsettlementterm": "P60D",
    "tradeandotherpayablesmaturityperiod": "P30D"
  },
  {
    "date": "2021-06-30",
    "symbol": "MEOBF",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2021-06-30",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MESO",
    "entityregistrantname": "MESOBLAST LTD",
    "entitycentralindexkey": 1345099,
    "currentfiscalyearenddate": "--06-30",
    "security12btitle": "American Depositary Shares, each representing five Ordinary Shares",
    "securityexchangename": "NASDAQ",
    "entityfilenumber": "001-37626",
    "entityincorporationstatecountrycode": "C3",
    "entityaddressaddressline1": "Level 38",
    "entityaddressaddressline2": "55 Collins Street",
    "entityaddresscityortown": "Melbourne",
    "entityaddresspostalzipcode": 3000,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentregistrationstatement": "false",
    "documentshellcompanyreport": "false",
    "icfrauditorattestationflag": "true",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "contactpersonnelname": "Silviu Itescu",
    "cityareacode": "+61 (3)",
    "localphonenumber": "9639 6036",
    "contactpersonnelfaxnumber": "+61 (3) 9639 6030",
    "entityaddresscountry": "AU",
    "entitywellknownseasonedissuer": "Yes",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Large Accelerated Filer",
    "entitycommonstocksharesoutstanding": 648696070,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entityinteractivedatacurrent": "Yes",
    "revenue": 7456000,
    "researchanddevelopmentexpense": 53012000,
    "manufacturingcommercialization": 32719000,
    "managementandadministrationexpense": 30867000,
    "fairvalueremeasurementofcontingentconsideration": -18687000,
    "otheroperatingincomeexpense": 1539000,
    "financecosts": 10714000,
    "profitlossbeforetax": -99630000,
    "incometaxexpensecontinuingoperations": -819000,
    "profitlossattributabletoownersofparent": -98811000,
    "basicearningslosspersharefromcontinuingoperations": -0.1633,
    "dilutedearningslosspersharefromcontinuingoperations": -0.1633,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": 1524000,
    "reclassificationadjustmentsonfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincomenetoftax": -209000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": -1315000,
    "comprehensiveincomeattributabletoownersofparent": -100126000,
    "equity": 1163153000,
    "profitloss": -98811000,
    "othercomprehensiveincome": 209000,
    "comprehensiveincome": 209000,
    "increasedecreasethroughothercontributionsbyowners": 106809000,
    "increasedecreasethroughtransactionswithowners": 106809000,
    "sharebasedcompensationforservicesrendered": 1867000,
    "taxcreditedordebitedtoequity": 91000,
    "increasedecreasethroughexerciseofoptions": 4894000,
    "increasedecreasethroughsharebasedpaymenttransactions": 12510000,
    "increasedecreasethroughexerciseofwarrantsequity": 12969000,
    "changesinequity": 4894000,
    "cashandcashequivalents": 136881000,
    "tradeandothercurrentreceivables": 4842000,
    "currentprepayments": 6504000,
    "currentassets": 148227000,
    "propertyplantandequipment": 3021000,
    "rightofuseassets": 9119000,
    "noncurrentfinancialassetsatfairvaluethroughothercomprehensiveincome": 2080000,
    "othernoncurrentassets": 1724000,
    "intangibleassetsandgoodwill": 580546000,
    "noncurrentassets": 596490000,
    "assets": 744717000,
    "tradeandothercurrentpayables": 19598000,
    "currentprovisions": 18710000,
    "currentportionoflongtermborrowings": 53200000,
    "currentleaseliabilities": 2765000,
    "currentliabilities": 94273000,
    "noncurrentprovisions": 17017000,
    "longtermborrowings": 41045000,
    "noncurrentleaseliabilities": 8485000,
    "deferredconsiderationnoncurrent": 2500000,
    "noncurrentliabilities": 69047000,
    "liabilities": 163320000,
    "netassetsliabilities": 581397000,
    "issuedcapital": 1163153000,
    "otherreserves": 65813000,
    "retainedearnings": -647569000,
    "commercializationrevenuereceived": 6121000,
    "governmentgrantsandtaxincentivesreceived": 68000,
    "paymentstosuppliersandemployeesinclusiveofgoodsandservicestax": 106920000,
    "interestreceivedclassifiedasoperatingactivities": 17000,
    "interestandothercostsoffinancepaidclassifiedasoperatingactivities": 5932000,
    "incometaxespaidrefundclassifiedasoperatingactivities": 35000,
    "cashflowsfromusedinoperatingactivities": -106681000,
    "investmentinfixedassets": -1647000,
    "cashflowsfromusedininvestingactivities": -1647000,
    "paymentsoftransactioncostsfromborrowings": 13000,
    "proceedsfromissuingshares": 106268000,
    "proceedsfromissuingwarrants": 12969000,
    "paymentsforshareissuecosts": 1827000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 2931000,
    "cashflowsfromusedinfinancingactivities": 114466000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 6138000,
    "effectofexchangeratechangesoncashandcashequivalents": 1415000,
    "principalrepaymentdueterm": "2021-03",
    "descriptionoflicenseandcollaborationagreement": "In November 2020, the Group entered into a license and collaboration agreement with Novartis for the development, manufacture, and commercialization of remestemcel-L, with an initial focus on the treatment of acute respiratory distress syndrome (ARDS) including that associated with COVID-19. The agreement remains subject to certain closing conditions, including time to analyze the results from the COVID-19 ARDS trial.",
    "commercializationrevenue": 7434000,
    "milestonerevenue": 2500000,
    "revenuefrominterest": 22000,
    "clinicaltrialrelatedresearchanddevelopment": 18569000,
    "manufacturingproductionanddevelopment": 31590000,
    "wagesandsalaries": 26804000,
    "definedcontributionsuperannuationexpenses": 379000,
    "decreaseincreasethroughtaxonsharebasedpaymenttransactions": 12510000,
    "employeebenefitsexpense": 39693000,
    "depreciationpropertyplantandequipment": 1016000,
    "depreciationrightofuseassets": 1691000,
    "intellectualpropertyamortization": 1557000,
    "amortisationexpense": 4264000,
    "overheadsandadministrationexpenses": 7757000,
    "consultancyexpenses": 5386000,
    "legalpatentandotherprofessionalfees": 6950000,
    "intellectualpropertyexpenses": 2389000,
    "othermanagementandadministrationexpenses": 22482000,
    "lossgainonremeasurementofcontingentconsideration": 18687000,
    "revenuefromgovernmentgrants": 68000,
    "foreignexchangegainslosses": 1471000,
    "financecostsgainsonremeasurementofborrowingarrangements": 5225000,
    "interestexpense": 15939000,
    "expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 12509744,
    "nonrefundableupfrontpaymentreceived": 17500000,
    "percentageofpatientstoprovideregulatoryharmonizationcostefficienciesandstreamlinedtimelines": 0.2,
    "nonrefundableupfrontpaymentsreceivable": 112500000,
    "cumulativemilestonepaymentsreachableamount": 1000000000,
    "taxexpenseincomeatapplicabletaxrate": -29889000,
    "sharebasedcompensationexpense": 2836000,
    "researchanddevelopmenttaxconcessions": -894000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 2000,
    "incometaxcontingentconsideration": -5606000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 121000,
    "currenttaxexpenseincome": -33119000,
    "adjustmentsforcurrenttaxofpriorperiod": -1000,
    "taxeffectofforeigntaxrates": 13218000,
    "incometaxbenefitnotrecognized": 19083000,
    "taxeffectonincreasedecreaseindeferredtaxassets": -482000,
    "increasedecreaseincurrenttaxliability": -482000,
    "taxrateeffectfromchangeintaxrate": 0.3,
    "increasedecreaseindeferredtaxassets": -1158000,
    "increasedecreaseindeferredtaxliabilities": -339000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -819000,
    "currenttaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": -525000,
    "deferredtaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": 905000,
    "currentanddeferredtaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": 380000,
    "deferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": 91000,
    "currentanddeferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": 91000,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 77738000,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": 7424000,
    "othertaxcreditsforwhichnodeferredtaxassetrecognised": 3220000,
    "deferredtaxassetsnotbroughttoaccount": 88382000,
    "taxeffectoftaxlosses": 424900000,
    "deferredtaxassets": 44400000,
    "deferredtaxassetexpirationperiod": "P11Y",
    "tradeandotherreceivables": 4842000,
    "financialassetsatfairvaluethroughothercomprehensiveincome": 2080000,
    "othernoncurrentfinancialassets": 1724000,
    "financialassets": 2080000,
    "borrowings": 94245000,
    "contingentconsiderations": 25409000,
    "financialliabilities": 25409000,
    "balanceswithbanks": 136430000,
    "depositsatcall": 451000,
    "interestbearingdepositsatcallheldassecurity": 500000,
    "tradereceivables": 2000000,
    "foreignwithholdingtaxrecoverable": 471000,
    "receivablefromtaxcredits": 1473000,
    "securitydeposits": 252000,
    "receivablesfromtaxesotherthanincometax": 646000,
    "clinicaltrialresearchanddevelopmentexpenditure": 2823000,
    "prepaidinsuranceandsubscriptions": 1921000,
    "otherprepayments": 1760000,
    "prepayments": 6504000,
    "tradereceivablessettlementperiod": "P60D",
    "gainslossesonfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincomenetoftax": 200000,
    "borrowingsmaturity": "March 2022",
    "principalrepaymentdate": "2022-03",
    "borrowingsinterestrate": 0.0945,
    "interestpayable": 2200000,
    "borrowingsinterestratebasis": "There is a four-year interest only period, until July 2022, with the principal repayable in equal quarterly instalments over the remaining period of the loan. The loan matures in July 2026. Interest on the loan will accrue at a fixed rate of 15% per annum.",
    "remeasurementofborrowingarrangements": 4800000,
    "loanadministrationfeepayablecurrent": 400000,
    "noncurrentfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincome": 2080000,
    "tradeandotherpayables": 19598000,
    "securedbankloansreceived": 80000000,
    "borrowingcostsrecognisedasexpense": 6751000,
    "borrowingcostscapitalised": 20996000,
    "shorttermborrowings": 53200000,
    "leaseliabilities": 11250000,
    "netdebt": -31386000,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": 2931000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": 2931000,
    "increasedecreaseinliabilitiesarisingfromfinancingactivities": 9069000,
    "remeasurementofborrowingarrangementsondebt": 5225000,
    "otherchangesondebtandleases": -13596000,
    "increasedecreaseinborrowingliabilitiesclassifiedasfinancingactivities": -9992000,
    "increasedecreaseinleaseliabilitiesarisingfromfinancingactivities": -3604000,
    "paymentstoacquireleaseliabilities": -395000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromfinancingactivities": -346000,
    "effectofforeignexchangeadjustmentsonliabilitiesarisingfromfinancingactivitiesandcashandcashequivalents": 1069000,
    "liabilitiesarisingfromfinancingactivities": -105495000,
    "financialassetsatfairvalue": 2080000,
    "financialliabilitiesatfairvalue": 25409000,
    "contingentconsiderationprovision": 25409000,
    "contingentconsiderationprovisionamountused": 1070000,
    "gainlossonremeasurementofcontingentconsiderationprovision": 18700000,
    "descriptionofvaluationtechniquesusedinfairvaluemeasurementliabilities": "Discounted cash flows",
    "descriptionofinputsusedinfairvaluemeasurementliabilities": "Risk adjusteddiscount rate",
    "percentageofweightedaverageofsignificantunobservableinputsliabilities": -0.125,
    "descriptionofinterrelationshipsbetweenunobservableinputsandofhowtheymightmagnifyormitigateeffectofchangesinunobservableinputsonfairvaluemeasurementliabilities": "Year ended 30 June, 2021: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.3%. Year ended June 30, 2020: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.4%.",
    "cashorstockpayableatfairvalueliabilities": 18328000,
    "royaltypaymentsatfairvalueliabilities": 7081000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 1427000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": -75000,
    "depreciationmethodpropertyplantandequipment": "Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over the estimated useful lives.",
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P3Y",
    "cashoutflowforleases": 3500000,
    "interestexpenseonleaseliabilities": 600000,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 3600000,
    "noncancellabletermofleaseandnonleasecomponents": "P4Y6M",
    "informationaboutlesseesexposurearisingfromextensionoptionsandterminationoptions": "As of June 30, 2021, the anticipated future contractual cash flows relating to the lease component of the Lonza agreement are $5.0 million on an undiscounted basis, as included within lease liabilities in Note 10(c). The anticipated future contractual cash flows exclude cashflows beyond the initial non-cancellable lease term of 4.5 years as it is not reasonably certain the Group will extend the agreement.",
    "minimumfinancialcommitmentofleasecomponent": 5000000,
    "amortisationmethodintangibleassetsotherthangoodwill": "7 – 16 years",
    "goodwill": 2100000,
    "numberofreportableoperatingsegment": 1,
    "inprocessresearchanddevelopmentrecognized": 387000000,
    "posttaxdiscountrates": 0.138,
    "expectedpatentexpiry": "P12Y",
    "currentprovisionsforaccruedannualleave": 1000000,
    "additionstorightofuseassets": 395000,
    "rightofuseassetsrevaluedassetsatcost": 2721000,
    "rightofuseassetsincreasedecreaseinrevaluationsurplus": 232000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 500000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": 1000,
    "amortisationintangibleassetsotherthangoodwill": 102000,
    "provisions": 25409000,
    "deferredtaxassetsattributabletotemporarydifferencesfromtaxlosses": 71916000,
    "deferredtaxassetsattributabletoothertemporarydifferences": 8248000,
    "deferredtaxliabilitiesattributabletotemporarydifferencesfromintangibleassets": 80164000,
    "deferredtaxliabilities": 80164000,
    "deferredtaxliabilityasset": -71916000,
    "netmovementinregulatorydeferralaccountbalancesrelatedtoprofitorlossandnetmovementinrelateddeferredtax": 1449000,
    "netmovementinregulatorydeferralaccountbalancesrelatedtodirectlytoequity": -466000,
    "deferredconsideration": 2500000,
    "numberofsharesissued": 648696070,
    "treasurysharespurchased": 771983,
    "numberofsharesoutstanding": 647924087,
    "ordinarysharespurchasedvalue": 1163153000,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 6178017,
    "numberofsharestransfertoemployeesharetrust": 3450000,
    "sharebasedcompensationforservicesrenderedshares": 1187168,
    "sharesavailableforissuanceunderissuanceplan": 60109290,
    "sharesissuedinplacementsvalue": 97031000,
    "shareissuerelatedcost": 1312000,
    "contributionsofequityduringperiod": 64746458,
    "contributionsofvalueforequityduringperiod": 106809000,
    "shareoptionsreservetransferredtoequityonexerciseofoptionsvalue": 4894000,
    "sharesheldintrust": 771983,
    "increasedecreasethroughtransfersandotherchangesequity": -91000,
    "valueofshareoptionsexercisedinsharebasedpaymentarrangement": -4894000,
    "gainslossesonexchangedifferencesontranslationnetoftax": -1524000,
    "equityreserveatfairvalue": 12969000,
    "weightedaverageshareprice2019": 2.42,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.6095,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0044,
    "adjustmentsfordepreciationandamortisationexpense": 4264000,
    "adjustmentsforunrealisedforeignexchangelossesgains": -1499000,
    "adjustmentsforfinanceincomecost": -10004000,
    "remeasurementofborrowingarrangementsnet": -5225000,
    "fairvalueremeasurementofcontingentconsiderationaftertax": -18687000,
    "adjustmentsforsharebasedpayments": 12510000,
    "adjustmentsfordeferredtaxexpense": -819000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -1739000,
    "adjustmentsforincreasedecreaseinprepayments": -213000,
    "adjustmentsforincreasedecreaseintradecreditorsandaccruals": -5061000,
    "adjustmentsforprovisions": -1405000,
    "percentageofcashheld": 0.89,
    "changeininterestrateeffectonprofitloss": 0.05,
    "effectonprofitfromchangeintaxrate": 0.1,
    "noninterestbearingfinancialliabilitiesmaturityperiod": "P6M",
    "percentageofforecastnetsales": 0.2,
    "increasenoncurrentborrowing": 200000,
    "decreaseinprofit": 200000,
    "decreasenoncurrentborrowings": 300000,
    "increaseinprofit": 300000,
    "percentageofdecreasenetsales": 0.2,
    "noncurrentfinancialliabilities": 52864000,
    "borrowingsadjustmenttointerestratebasis": 0.55,
    "currentfinancialliabilities": 52864000,
    "borrowingsinterestratepercentage": 0.097,
    "increaseininterestratepercentage": 0.1019,
    "decreaseininterestratepercentage": 0.0922,
    "effectofincreaseininterestratechangeofborrowingsonprofit": 243000,
    "effectofdecreaseininterestratechangeofborrowingsonprofit": 243000,
    "fundsinvestedpercentage": 0.0024,
    "fundsinvestedwhichderivesinterestrevenue": 107564000,
    "increaseininterestrateonfundsinvestedwhichderivesinterestrevenue": 32000,
    "decreaseininterestrateonfundsinvestedwhichderivesinterestrevenue": 32000,
    "effectonprofitfromchangeininterestrateincreaseordecrease": 0.1,
    "percentageofpriceratechangesinnoncurrentborrowings": 0.45,
    "percentageofpriceratechangesinborrowings": 0.45,
    "receivablesfromotherparties": 2122000,
    "receivablesfromincometax": 3000,
    "receivablefromforeignwithholdingtax": 400000,
    "receivablesfrombankdeposits": 257000,
    "derivativefinancialliabilitiesundiscountedcashflows": -57378000,
    "grossloancommitments": 94245000,
    "nameofsubsidiary": "Mesoblast, Inc.",
    "countryofincorporationorresidenceofsubsidiary": "USA",
    "proportionofownershipinterestsheldbynoncontrollinginterests": 1,
    "milestonepayment": 2200000,
    "minimumremainingfinancialcommitmentofnonleasecomponentonexerciseofoptiontoextendnoncancellableterm": 24000000,
    "minimumfinancialcommitmentofleasecomponentonexerciseofoptiontoextendnoncancellableterm": 5000000,
    "noncancellablepurchasecommitments": 9600000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 2401749,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 12646,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 36444,
    "keymanagementpersonnelcompensationsharebasedpayment": 1469698,
    "keymanagementpersonnelcompensation": 3920537,
    "dateofgrantofsharebasedpaymentarrangement": "In accordance with the Company’s policy, options and loan funded shares are typically issued in three equal tranches. For issues granted prior to July 1, 2015 the length of time from grant date to expiry date was typically 5 years. Grants since July 1, 2015, are issued with a seven year term.",
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met.",
    "percentageofpremiumattachedwithtimebasedvestingconditionoptions": 0.1,
    "employeeshareoptionplanmaximumnumberofoptionsavailableforissuance": 10000000,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 4.42,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsandloanfunded": "P4Y5M26D",
    "numberoftranchesofshareplangranted": 3,
    "expirytermofoptions": "P5Y",
    "tranchevestingterm": "P1Y",
    "optionexerciseterminconnectionwithcessationofemployment": "P60D",
    "optionsconversionratio": 63.978,
    "optionsvestedonacquisitiondate": "2010-12-07",
    "numberofequaltranchesvestondate": 2,
    "numberofequaltranchespriortovesting": 2,
    "explanationofmodificationsmodifiedsharebasedpaymentarrangements": "no",
    "weightedaveragesharepriceshareoptionsgranted2019": 3.56,
    "closingsharemarketpriceofordinaryshare": 1.98,
    "sharebasedpaymentsarrangementexpirationdate": "30-Jun-22",
    "exercisepriceofoutstandingshareoptions2019": 2.51,
    "numberofoutstandingshareoptions": 1753334,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 1500000,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 10000,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 1753334,
    "weightedaverageexercisepriceofshareoptionsinsharebasedpaymentarrangementexercisedduringperiodatdateofexercise2019": 2.06,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 2.76,
    "weightedaveragesharepriceexercisableinsharebasedpaymentarrangement": 2.15,
    "valuationdate": "28-Jul-20",
    "sharepriceatacceptancedate": 3.6,
    "expectedlifeafterfactoring": "P6Y1M6D",
    "auditorsremunerationforauditservices": 747783,
    "auditorsremunerationforotherservices": 91750,
    "auditorsremuneration": 839533,
    "basicearningslosspershare": -0.1633,
    "dilutedearningslosspershare": -0.1633,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententity": -98811000,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -98811000,
    "profitlossattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -98811000,
    "weightedaverageshares": 605064036,
    "adjustedweightedaverageshares": 605064036,
    "reserveofexchangedifferencesontranslation": -150306000,
    "reserveofsharebasedpayments": 77310000,
    "warrantreserve": 12969000,
    "numberofoperatingsegment": 1,
    "deferredconsiderationmilestoneconsiderationrecognized": 20000000,
    "amountentitledtobereceivedonnonrefundableupfrontpaymentuponreachingproductregulatorymilestone": 25000000,
    "revenuefromroyalties": 200000,
    "royaltiesreceivableundersalesbasedmilestones": 7200000,
    "descriptionofeligibilityonrefundabletaxoffset": "A refundable tax offset is available to eligible companies with an annual aggregate turnover of less than A$20.0 million. Eligible companies can receive a refundable tax offset for a percentage of their research and development spending. For the years ended June 30, 2021 and 2020, the rate of the refundable tax offset is 43.5%",
    "annualaggregateturnoveramount": 20000000,
    "percentageofresearchanddevelopmenttoreceiverefundabletaxoffset": 0.435,
    "prelaunchinventoryrecognized": 21900000,
    "tradeandotherreceivablesdueforsettlementterm": "P60D",
    "tradeandotherpayablesmaturityperiod": "P30D"
  },
  {
    "date": "2020-06-30",
    "symbol": "MEOBF",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2020-06-30",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MESO",
    "entityregistrantname": "MESOBLAST LTD",
    "entitycentralindexkey": 1345099,
    "currentfiscalyearenddate": "--06-30",
    "security12btitle": "American Depositary Shares, each representing five Ordinary Shares",
    "securityexchangename": "NASDAQ",
    "entityfilenumber": "001-37626",
    "entityincorporationstatecountrycode": "C3",
    "entityaddressaddressline1": "Level 38",
    "entityaddressaddressline2": "55 Collins Street",
    "entityaddresscityortown": "Melbourne",
    "entityaddresspostalzipcode": 3000,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentregistrationstatement": "false",
    "documentshellcompanyreport": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "contactpersonnelname": "Silviu Itescu",
    "cityareacode": "+61 (3)",
    "localphonenumber": "9639 6036",
    "contactpersonnelfaxnumber": "+61 (3) 9639 6030",
    "entityaddresscountry": "AU",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Accelerated Filer",
    "entitycommonstocksharesoutstanding": 583949612,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entityinteractivedatacurrent": "Yes",
    "revenue": 20000000,
    "researchanddevelopmentexpense": 56188000,
    "manufacturingcommercialization": 25309000,
    "managementandadministrationexpense": 25609000,
    "fairvalueremeasurementofcontingentconsideration": -1380000,
    "otheroperatingincomeexpense": -455000,
    "financecosts": 13330000,
    "profitlossbeforetax": -87355000,
    "incometaxexpensecontinuingoperations": -9415000,
    "profitlossattributabletoownersofparent": -77940000,
    "basicearningslosspersharefromcontinuingoperations": -0.1474,
    "dilutedearningslosspersharefromcontinuingoperations": -0.1474,
    "reclassificationadjustmentsonfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincomenetoftax": -446000,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": -1146000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": 700000,
    "comprehensiveincomeattributabletoownersofparent": -77240000,
    "equity": 758129000,
    "cumulativeeffectofadjustmentonadoptionofifrs16": 827000,
    "profitloss": -16981000,
    "othercomprehensiveincome": 700000,
    "comprehensiveincome": -16981000,
    "increasedecreasethroughothercontributionsbyowners": 137840000,
    "increasedecreasethroughtransactionswithowners": 137840000,
    "sharebasedcompensationforservicesrendered": 864000,
    "taxcreditedordebitedtoequity": 979000,
    "increasedecreasethroughexerciseofoptions": 4364000,
    "increasedecreasethroughsharebasedpaymenttransactions": 7522000,
    "changesinequity": 8501000,
    "cashandcashequivalents": 129328000,
    "tradeandothercurrentreceivables": 1574000,
    "currentprepayments": 5646000,
    "currentassets": 22715000,
    "propertyplantandequipment": -8253000,
    "rightofuseassets": -2133000,
    "noncurrentfinancialassetsatfairvaluethroughothercomprehensiveincome": 1871000,
    "othernoncurrentassets": 1473000,
    "intangibleassetsandgoodwill": 102698000,
    "noncurrentassets": 597054000,
    "assets": 775407000,
    "tradeandothercurrentpayables": 24972000,
    "currentprovisions": 3750000,
    "currentportionoflongtermborrowings": 32455000,
    "currentleaseliabilities": 3519000,
    "deferredconsiderationcurrent": 10000000,
    "currentliabilities": 11765000,
    "netdeferredtaxliabilities": 730000,
    "noncurrentprovisions": 2013000,
    "longtermborrowings": 35072000,
    "noncurrentleaseliabilities": 6317000,
    "deferredconsiderationnoncurrent": 2500000,
    "noncurrentliabilities": 94133000,
    "liabilities": 17278000,
    "netassetsliabilities": 549326000,
    "issuedcapital": 1051450000,
    "otherreserves": -38267000,
    "retainedearnings": -146576000,
    "commercializationrevenuereceived": 7676000,
    "upfrontandmilestonepaymentsreceived": 17500000,
    "governmentgrantsandtaxincentivesreceived": 1577000,
    "paymentstosuppliersandemployeesinclusiveofgoodsandservicestax": 77710000,
    "interestreceivedclassifiedasoperatingactivities": 546000,
    "interestandothercostsoffinancepaidclassifiedasoperatingactivities": 5947000,
    "incometaxespaidrefundclassifiedasoperatingactivities": 7000,
    "cashflowsfromusedinoperatingactivities": -56365000,
    "investmentinfixedassets": -2096000,
    "paymentsforcontingentconsideration": 1027000,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 150000,
    "cashflowsfromusedininvestingactivities": -3273000,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 512000,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 512000,
    "proceedsfromissuingshares": 144946000,
    "paymentsforshareissuecosts": 6277000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 1625000,
    "cashflowsfromusedinfinancingactivities": 137044000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 77406000,
    "effectofexchangeratechangesoncashandcashequivalents": 1496000,
    "expectedfundingfromexistingstrategicandfinancingpartnerships": 67500000,
    "termofshorttermlease": "12 months or less",
    "principalrepaymentdueterm": "2022-03",
    "principalrepaymentduecommenceterm": "2020-10",
    "shorttermborrowings": 4506000,
    "commercializationrevenue": 6614000,
    "milestonerevenue": 25000000,
    "revenuefrominterest": 542000,
    "clinicaltrialrelatedresearchanddevelopment": 24565000,
    "manufacturingproductionanddevelopment": 23944000,
    "wagesandsalaries": 25100000,
    "definedcontributionsuperannuationexpenses": 327000,
    "decreaseincreasethroughtaxonsharebasedpaymenttransactions": 7521745,
    "employeebenefitsexpense": 32949000,
    "depreciationpropertyplantandequipment": 190000,
    "depreciationrightofuseassets": 2133000,
    "intellectualpropertyamortization": 1574000,
    "amortisationexpense": 3667000,
    "overheadsandadministrationexpenses": 8276000,
    "consultancyexpenses": 5168000,
    "legalpatentandotherprofessionalfees": 5854000,
    "intellectualpropertyexpenses": 2683000,
    "othermanagementandadministrationexpenses": 21981000,
    "lossgainonremeasurementofcontingentconsideration": -1380000,
    "gainlossonremeasurementofborrowingarrangements": -779000,
    "revenuefromgovernmentgrants": 78000,
    "foreignexchangegainslosses": 246000,
    "financecostsgainsonremeasurementofborrowingarrangements": 100000,
    "interestexpense": 14716000,
    "expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 7521745,
    "nonrefundableupfrontpaymentsreceivable": 132500000,
    "numberofperformanceobligations": 3,
    "standalonesellingprice": 10000000,
    "taxexpenseincomeatapplicabletaxrate": -26207000,
    "sharebasedcompensationexpense": 1367000,
    "researchanddevelopmenttaxconcessions": -876000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -98000,
    "incometaxcontingentconsideration": -414000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 97000,
    "currenttaxexpenseincome": -25904000,
    "adjustmentsforcurrenttaxofpriorperiod": 283000,
    "taxeffectofforeigntaxrates": 9397000,
    "incometaxbenefitnotrecognized": 6809000,
    "taxeffectonincreasedecreaseindeferredtaxassets": -3412000,
    "increasedecreaseincurrenttaxliability": -3412000,
    "increasedecreaseindeferredtaxassets": -12687000,
    "increasedecreaseindeferredtaxliabilities": -3272000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -9415000,
    "applicabletaxrate": 0.21,
    "deferredtaxassetsnotbroughttoaccount": 65575000,
    "currenttaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": -2293000,
    "deferredtaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": 1266000,
    "currentanddeferredtaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": -1027000,
    "deferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": -979000,
    "currentanddeferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": -979000,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 55573000,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": 6782000,
    "othertaxcreditsforwhichnodeferredtaxassetrecognised": 3220000,
    "tradeandotherreceivables": 1574000,
    "financialassetsatfairvaluethroughothercomprehensiveincome": 1871000,
    "othernoncurrentfinancialassets": 3311000,
    "financialassets": 136084000,
    "borrowings": 39578000,
    "contingentconsiderations": 45166000,
    "financialliabilities": 159616000,
    "balanceswithbanks": 128916000,
    "depositsatcall": 412000,
    "interestbearingdepositsatcallheldassecurity": 400000,
    "tradereceivables": 678000,
    "foreignwithholdingtaxrecoverable": 471000,
    "securitydeposits": 252000,
    "receivablesfromtaxesotherthanincometax": 171000,
    "clinicaltrialresearchanddevelopmentexpenditure": 3304000,
    "prepaidinsuranceandsubscriptions": 1337000,
    "otherprepayments": 1005000,
    "prepayments": 5646000,
    "tradereceivablessettlementperiod": "P60D",
    "gainslossesonfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincomenetoftax": -400000,
    "undrawnborrowingfacilities": 25000000,
    "borrowingsmaturity": "March 2022",
    "principalrepaymentdate": "2022-03",
    "borrowingsinterestrate": 0.097,
    "interestpayable": 3600000,
    "borrowingsinterestratebasis": "There is a four-year interest only period, until July 2022, with the principal repayable in equal quarterly instalments over the remaining period of the loan. The loan matures in July 2026. Interest on the loan will accrue at a fixed rate of 15% per annum.",
    "loanadministrationfeepayablecurrent": 300000,
    "remeasurementofborrowingarrangements": 800000,
    "noncurrentfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincome": 1871000,
    "tradeandotherpayables": 24972000,
    "securedbankloansreceived": 80000000,
    "borrowingcostsrecognisedasexpense": 6738000,
    "borrowingcostscapitalised": 16216000,
    "shorttermborrowingsincludingleaseliabilities": 35974000,
    "longtermborrowingsincludingleaseliabilities": 63340000,
    "netdebt": -30014000,
    "leaseliabilities": 9836000,
    "liabilitiesarisingfromfinancingactivities": -99314000,
    "cashflowsadjustmentsondebt": 5443000,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": 2078000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": 7521000,
    "increasedecreaseinliabilitiesarisingfromfinancingactivities": 84927000,
    "remeasurementofborrowingarrangementsondebt": 607000,
    "otherchangesondebtandleases": -16299000,
    "increasedecreaseinborrowingliabilitiesclassifiedasfinancingactivities": -14242000,
    "increasedecreaseinleaseliabilitiesarisingfromfinancingactivities": -2057000,
    "paymentstoacquireleaseliabilities": -4083000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromfinancingactivities": 1000,
    "effectofforeignexchangeadjustmentsonliabilitiesarisingfromfinancingactivitiesandcashandcashequivalents": 1497000,
    "financialassetsatfairvalue": 1871000,
    "financialliabilitiesatfairvalue": 45166000,
    "contingentconsiderationprovision": 45166000,
    "contingentconsiderationprovisionamountused": 988000,
    "gainlossonremeasurementofcontingentconsiderationprovision": 1300000,
    "descriptionofvaluationtechniquesusedinfairvaluemeasurementliabilities": "Discounted cash flows",
    "descriptionofinputsusedinfairvaluemeasurementliabilities": "Expected salesvolumes",
    "percentageofweightedaverageofsignificantunobservableinputsliabilities": 0.13,
    "descriptionofinterrelationshipsbetweenunobservableinputsandofhowtheymightmagnifyormitigateeffectofchangesinunobservableinputsonfairvaluemeasurementliabilities": "Year ended June 30, 2020: A 10% increase/decrease in sales volume assumptions adopted would increase/decrease the fair value by 3%.Year ended June 30, 2019: A 10% increase/decrease in sales volume assumptions adopted would increase/decrease the fair value by 4%.",
    "cashorstockpayableatfairvalueliabilities": 28801000,
    "royaltypaymentsatfairvalueliabilities": 16365000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 2003000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 50000,
    "disposalspropertyplantandequipment": 1000,
    "depreciationmethodpropertyplantandequipment": "Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over the estimated useful lives.",
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P4Y",
    "cashoutflowforleases": 2400000,
    "interestexpenseonleaseliabilities": 500000,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 600000,
    "noncancellabletermofleaseandnonleasecomponents": "P4Y6M",
    "minimumfinancialcommitmentofleasecomponent": 5300000,
    "conditionalreductioninminimumfinancialcommitmentofleasecomponent": 2000000,
    "amortisationmethodintangibleassetsotherthangoodwill": "15 – 20 years",
    "numberofreportableoperatingsegment": 1,
    "posttaxdiscountrates": 0.155,
    "currentprovisionsforaccruedannualleave": 800000,
    "additionstorightofuseassets": 3844000,
    "rightofuseassetsrevaluedassetsatcost": 1319000,
    "rightofuseassetsincreasedecreaseinrevaluationsurplus": 51000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 50000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": -1000,
    "amortisationintangibleassetsotherthangoodwill": 1574000,
    "provisions": 56760000,
    "deferredtaxassetsattributabletotemporarydifferencesfromtaxlosses": 72899000,
    "deferredtaxassetsattributabletoothertemporarydifferences": 6196000,
    "deferredtaxassets": 79095000,
    "deferredtaxliabilitiesattributabletotemporarydifferencesfromintangibleassets": 79825000,
    "deferredtaxliabilities": 79825000,
    "deferredtaxassetsexpectedtobesettledaftertwelvemonths": 79095000,
    "deferredtaxliabilitiesexpectedtobesettledwithintwelvemonths": 99000,
    "deferredtaxliabilitiesexpectedtobesettledaftertwelvemonths": 79726000,
    "deferredtaxliabilityasset": 730000,
    "netmovementinregulatorydeferralaccountbalancesrelatedtoprofitorlossandnetmovementinrelateddeferredtax": -9415000,
    "netmovementinregulatorydeferralaccountbalancesrelatedtodirectlytoequity": -979000,
    "deferredconsideration": 2500000,
    "deferredconsiderationmilestoneconsiderationreceived": 2500000,
    "deferredconsiderationrevenuerecognized": 10000000,
    "deferredconsiderationupfrontmilestonereceivablerecognized": 20000000,
    "numberofsharesissued": 583949612,
    "treasurysharespurchased": 3500000,
    "numberofsharesoutstanding": 580449612,
    "ordinarysharespurchasedvalue": 1051450000,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 4823404,
    "sharebasedcompensationforservicesrenderedshares": 600000,
    "sharesavailableforissuanceunderissuanceplan": 80500000,
    "issued": 85323404,
    "sharesissuedinplacementsvalue": 139483000,
    "shareissuerelatedcost": 6871000,
    "sharesissuedamountduringperiod": 137840000,
    "contributionsofvalueforequityduringperiod": 137840000,
    "contributionsofequityduringperiod": 85323404,
    "shareoptionsreservetransferredtoequityonexerciseofoptionsvalue": 3205000,
    "increasedecreasethroughtransfersandotherchangesequity": 979000,
    "valueofshareoptionsexercisedinsharebasedpaymentarrangement": -3205000,
    "gainslossesonexchangedifferencesontranslationnetoftax": 1146000,
    "adjustmentsfordepreciationandamortisationexpense": 3667000,
    "adjustmentsforunrealisedforeignexchangelossesgains": -302000,
    "adjustmentsforfinanceincomecost": -8800000,
    "remeasurementofborrowingarrangementsnet": -607000,
    "fairvalueremeasurementofcontingentconsiderationaftertax": -1380000,
    "adjustmentsforsharebasedpayments": 7522000,
    "adjustmentsfordeferredtaxexpense": -9415000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 890000,
    "adjustmentsforincreasedecreaseinprepayments": 2292000,
    "adjustmentsfordecreaseincreaseintaxassets": 1499000,
    "adjustmentsforincreasedecreaseintradecreditorsandaccruals": 12508000,
    "adjustmentsforprovisions": 3601000,
    "adjustmentsforincreasedecreaseindeferredconsideration": -7500000,
    "percentageofcashheld": 0.14,
    "changeininterestrateeffectonprofitloss": 0.05,
    "effectonprofitfromchangeintaxrate": 0.1,
    "noninterestbearingfinancialliabilitiesmaturityperiod": "P6M",
    "percentageofforecastnetsales": 0.2,
    "increasenoncurrentborrowing": 5300000,
    "decreaseinprofit": 5300000,
    "decreasenoncurrentborrowings": 3100000,
    "increaseinprofit": 3100000,
    "percentageofdecreasenetsales": 0.2,
    "noncurrentfinancialliabilities": 49900000,
    "borrowingsadjustmenttointerestratebasis": 0.56,
    "currentfinancialliabilities": 49900000,
    "borrowingsinterestratepercentage": 0.097,
    "increaseininterestratepercentage": 0.0095,
    "decreaseininterestratepercentage": 0.0077,
    "effectofincreaseininterestratechangeofborrowingsonprofit": 243000,
    "effectofdecreaseininterestratechangeofborrowingsonprofit": 243000,
    "fundsinvestedpercentage": 0.0086,
    "fundsinvestedwhichderivesinterestrevenue": 600000,
    "increaseininterestrateonfundsinvestedwhichderivesinterestrevenue": 1000,
    "decreaseininterestrateonfundsinvestedwhichderivesinterestrevenue": 1000,
    "effectonprofitfromchangeininterestrateincreaseordecrease": 0.1,
    "percentageofpriceratechangesincurrentborrowings": 0.05,
    "percentageofpriceratechangesinnoncurrentborrowings": 0.39,
    "percentageofpriceratechangesinborrowings": 0.44,
    "receivablesfromotherparties": 801000,
    "receivablefromforeignwithholdingtax": 400000,
    "receivablesfrombankdeposits": 250000,
    "valueaddedtaxreceivables": 2000,
    "receivablefromtaxcredits": 1473000,
    "derivativefinancialliabilitiesundiscountedcashflows": -176810000,
    "grossloancommitments": 124286000,
    "nameofsubsidiary": "BeiCell Ltd",
    "countryofincorporationorresidenceofsubsidiary": "Cayman Islands",
    "proportionofownershipinterestsheldbynoncontrollinginterests": 1,
    "milestonepayment": 2200000,
    "commitmentsfordevelopmentoracquisitionofbiologicalassets": 49500000,
    "minimumfinancialcommitmentofnonleasecomponent": 44200000,
    "conditionalreductioninminimumfinancialcommitment": 28300000,
    "conditionalreductioninminimumfinancialcommitmentofnonleasecomponent": 26300000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 2483862,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 11366,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 34294,
    "keymanagementpersonnelcompensationsharebasedpayment": 1146965,
    "keymanagementpersonnelcompensation": 3676487,
    "dateofgrantofsharebasedpaymentarrangement": "25-Nov-19",
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met.",
    "percentageofpremiumattachedwithtimebasedvestingconditionoptions": 0.1,
    "employeeshareoptionplanmaximumnumberofoptionsavailableforissuance": 10000000,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 3.47,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsandloanfunded": "P4Y9M14D",
    "numberoftranchesofshareplangranted": 3,
    "expirytermofoptions": "P7Y",
    "tranchevestingterm": "P3Y",
    "optionexerciseterminconnectionwithcessationofemployment": "P60D",
    "optionsconversionratio": 63.978,
    "optionsvestedonacquisitiondate": "2010-12-07",
    "numberofequaltranchesvestondate": 5,
    "numberofequaltranchespriortovesting": 3,
    "exercisepriceofoutstandingshareoptions2019": 1.98,
    "explanationofmodificationsmodifiedsharebasedpaymentarrangements": "no",
    "weightedaveragesharepriceshareoptionsgranted2019": 1.07,
    "closingsharemarketpriceofordinaryshare": 3.25,
    "sharebasedpaymentsarrangementexpirationdate": "24-Nov-26",
    "numberofoutstandingshareoptions": 38911491,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 17490334,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 1493332,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 15373646,
    "weightedaverageshareprice2019": 1.86,
    "weightedaverageexercisepriceofshareoptionsinsharebasedpaymentarrangementexercisedduringperiodatdateofexercise2019": 1.6,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 2.8,
    "weightedaveragesharepriceexercisableinsharebasedpaymentarrangement": 2.25,
    "valuationdate": "10-Apr-20",
    "sharepriceatacceptancedate": 1.97,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.5765,
    "expectedlifeafterfactoring": "P5Y10M24D",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0045,
    "auditorsremunerationforauditservices": 108262,
    "auditorsremunerationforotherservices": 14097,
    "auditorsremuneration": 835820,
    "basicearningslosspershare": -0.1474,
    "dilutedearningslosspershare": -0.1474,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententity": -77940000,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -77940000,
    "profitlossattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -77940000,
    "weightedaverageshares": 528821630,
    "adjustedweightedaverageshares": 528821630,
    "reserveofexchangedifferencesontranslation": -216440000,
    "reserveofsharebasedpayments": 69695000,
    "numberofoperatingsegment": 1,
    "deferredconsiderationmilestoneconsiderationrecognized": 20000000,
    "amountentitledtobereceivedonnonrefundableupfrontpaymentuponreachingproductregulatorymilestone": 25000000,
    "royaltiesreceivableundersalesbasedmilestones": 6600000,
    "descriptionofeligibilityonrefundabletaxoffset": "A refundable tax offset is available to eligible companies with an annual aggregate turnover of less than A$20.0 million. Eligible companies can receive a refundable tax offset for a percentage of their research and development spending. For the years ended June 30, 2020 and 2019, the rate of the refundable tax offset is 43.5%",
    "annualaggregateturnoveramount": 20000000,
    "percentageofresearchanddevelopmenttoreceiverefundabletaxoffset": 0.435,
    "prelaunchinventoryrecognized": 8800000,
    "tradeandotherreceivablesdueforsettlementterm": "P60D",
    "tradeandotherpayablesmaturityperiod": "P60D",
    "operatingincomelossonremeasurementofborrowingarrangements": 800000
  },
  {
    "date": "2019-06-30",
    "symbol": "MEOBF",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2019-06-30",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MESO",
    "entityregistrantname": "MESOBLAST LTD",
    "entitycentralindexkey": 1345099,
    "currentfiscalyearenddate": "--06-30",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Accelerated Filer",
    "entitycommonstocksharesoutstanding": 498626208,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "revenue": 20000000,
    "researchanddevelopmentexpense": 59815000,
    "manufacturingcommercialization": 15358000,
    "managementandadministrationexpense": 21625000,
    "fairvalueremeasurementofcontingentconsideration": 6264000,
    "otheroperatingincomeexpense": -1086000,
    "financecosts": 11328000,
    "profitlossbeforetax": -98754000,
    "incometaxexpensecontinuingoperations": -8955000,
    "profitlossattributabletoownersofparent": -89799000,
    "basicearningslosspersharefromcontinuingoperations": -0.1816,
    "dilutedearningslosspersharefromcontinuingoperations": -0.1816,
    "reclassificationadjustmentsonfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincomenetoftax": -4000,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": 137000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": -141000,
    "comprehensiveincomeattributabletoownersofparent": -89940000,
    "equity": 637830000,
    "profitloss": -23094000,
    "othercomprehensiveincome": -141000,
    "comprehensiveincome": -23094000,
    "increasedecreasethroughothercontributionsbyowners": 19441000,
    "increasedecreasethroughtransactionswithowners": 19441000,
    "sharebasedcompensationforservicesrendered": 1170000,
    "increasedecreasethroughexerciseofoptions": 258000,
    "increasedecreasethroughsharebasedpaymenttransactions": 4363000,
    "incrementalfairvaluegrantedmodifiedsharebasedpaymentarrangements": 10000,
    "changesinequity": 5543000,
    "cashandcashequivalents": 50426000,
    "tradeandothercurrentreceivables": 4060000,
    "currentprepayments": 8036000,
    "currentassets": 6723000,
    "propertyplantandequipment": -7708000,
    "noncurrentfinancialassetsatfairvaluethroughothercomprehensiveincome": 2317000,
    "othernoncurrentassets": 1200000,
    "intangibleassetsandgoodwill": 102698000,
    "noncurrentassets": 589593000,
    "assets": 643708000,
    "tradeandothercurrentpayables": 13060000,
    "currentprovisions": 2000000,
    "currentportionoflongtermborrowings": 13600000,
    "deferredconsiderationcurrent": 10000000,
    "currentliabilities": 5792000,
    "netdeferredtaxliabilities": 11124000,
    "noncurrentprovisions": 1742000,
    "longtermborrowings": 32660000000,
    "noncurrentliabilities": 126732000,
    "liabilities": 5878000,
    "netassetsliabilities": 481052000,
    "issuedcapital": 910405000,
    "otherreserves": -39413000,
    "retainedearnings": -128747000,
    "commercializationrevenuereceived": 4359000,
    "milestonepaymentreceived": 26409000,
    "researchanddevelopmenttaxincentivereceived": 1654000,
    "paymentstosuppliersandemployeesinclusiveofgoodsandservicestax": 86294000,
    "interestreceivedclassifiedasoperatingactivities": 726000,
    "interestandothercostsoffinancepaidclassifiedasoperatingactivities": 4641000,
    "incometaxespaidrefundclassifiedasoperatingactivities": 3000,
    "cashflowsfromusedinoperatingactivities": -57790000,
    "investmentinfixedassets": -279000,
    "paymentsforcontingentconsideration": 721000,
    "cashflowsfromusedininvestingactivities": -1000000,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 32660000,
    "paymentsoftransactioncostsfromborrowings": 1614000,
    "proceedsfromissuingshares": 30258000,
    "paymentsforshareissuecosts": 608000,
    "cashflowsfromusedinfinancingactivities": 71608000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 12818000,
    "effectofexchangeratechangesoncashandcashequivalents": -155000,
    "sharesissuedamountduringperiod": 20611000,
    "exciseperiodofissuanceofordinaryshares": "2019-12-31",
    "maximumadditionalamountavailablesubjecttoachievementofmilestones": 35000000,
    "deferredconsiderationupfrontmilestonereceivablerecognized": 20000000,
    "amountentitledtobereceivedonnonrefundableupfrontpaymentuponreachingproductregulatorymilestone": 25000000,
    "proceedsfromstrategicalliance": 20000000,
    "revenuerecognizedrelationtopatentlicenseagreement": 1000000,
    "milestonerevenue": 1000000,
    "royaltiesreceivableundersalesbasedmilestones": 5000000,
    "leaseliabilities": 5600000,
    "rightofuseassets": 4700000,
    "reductioninretainedearnings": 900000,
    "deferredconsiderationrevenuerecognized": 10000000,
    "commercializationrevenue": 5003000,
    "revenuefrominterest": 719000,
    "clinicaltrialrelatedresearchanddevelopment": 37927000,
    "manufacturingproductionanddevelopment": 10912000,
    "wagesandsalaries": 19504000,
    "definedcontributionsuperannuationexpenses": 339000,
    "decreaseincreasethroughtaxonsharebasedpaymenttransactions": 4368000,
    "employeebenefitsexpense": 24211000,
    "depreciationpropertyplantandequipment": 212000,
    "intellectualpropertyamortization": 1577000,
    "amortisationexpense": 2139000,
    "overheadsandadministrationexpenses": 11356000,
    "consultancyexpenses": 3360000,
    "legalpatentandotherprofessionalfees": 4098000,
    "intellectualpropertyexpenses": 2795000,
    "othermanagementandadministrationexpenses": 21609000,
    "lossgainonremeasurementofcontingentconsideration": 6264000,
    "gainlossonremeasurementofborrowingarrangements": -752000,
    "researchanddevelopmenttaxincentiveexpense": -74000,
    "foreignexchangegainslosses": -208000,
    "foreignwithholdingtaxespaid": 52000,
    "financecostsgainsonremeasurementofborrowingarrangements": 376000,
    "interestexpense": 11704000,
    "expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 4988391,
    "othergainslosses": -100000,
    "otherincome": 100000,
    "taxexpenseincomeatapplicabletaxrate": -29626000,
    "sharebasedcompensationexpense": 1221000,
    "researchanddevelopmenttaxconcessions": -1486000,
    "netforeignexchangeloss": 15000,
    "incometaxcontingentconsideration": 1880000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 91000,
    "currenttaxexpenseincome": -27935000,
    "adjustmentsforcurrenttaxofpriorperiod": 18200000,
    "taxeffectofforeigntaxrates": 14000000,
    "incometaxbenefitnotrecognized": 12934000,
    "increasedecreaseindeferredtaxassets": -8856000,
    "increasedecreaseindeferredtaxliabilities": 99000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -8955000,
    "applicabletaxrate": 0.21,
    "taxrateeffectfromchangeintaxrate": 0.3,
    "deferredtaxassetsnotbroughttoaccount": 58157000,
    "currenttaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": -390000,
    "deferredtaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": 879000,
    "currentanddeferredtaxrelatingtoitemschargedorcreditedamountsthatwouldberecognizeddirectlyinequityifbroughttoaccount": 489000,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 51807000,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": 3130000,
    "othertaxcreditsforwhichnodeferredtaxassetrecognised": 3220000,
    "tradeandotherreceivables": 4060000,
    "financialassetsatfairvaluethroughothercomprehensiveincome": 2317000,
    "othernoncurrentfinancialassets": 3324000,
    "financialassets": 60127000,
    "borrowings": 33060000000,
    "contingentconsiderations": 47534000,
    "financialliabilities": 141880000,
    "balanceswithbanks": 50005000,
    "depositsatcall": 421000,
    "interestbearingdepositsatcallheldassecurity": 400000,
    "tradereceivables": 1739000,
    "incometaxandtaxincentivesrecoverable": 1511000,
    "foreignwithholdingtaxrecoverable": 471000,
    "securitydeposits": 300000,
    "otherdebtors": 2000,
    "receivablesfromtaxesotherthanincometax": 84000,
    "interestreceivable": 1000,
    "clinicaltrialresearchanddevelopmentexpenditure": 6042000,
    "prepaidinsuranceandsubscriptions": 1095000,
    "otherprepayments": 899000,
    "prepayments": 8036000,
    "tradereceivablessettlementperiod": "P60D",
    "gainslossesonfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincomenetoftax": -4000,
    "borrowingsinterestrate": 0.0945,
    "gainonremeasurementofborrowingarrangements": 400000,
    "undrawnborrowingfacilities": 25000000,
    "remeasurementofborrowingarrangements": 700000,
    "noncurrentfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincome": 2317000,
    "tradeandotherpayables": 13060000,
    "currentsecuredbankloansreceivedandcurrentportionofnoncurrentsecuredbankloansreceived": 14007000,
    "shorttermborrowings": 400000000,
    "noncurrentportionofnoncurrentsecuredbankloansreceived": 65601000,
    "borrowingcostsrecognisedasexpense": 6738000,
    "borrowingcostscapitalised": 8416000,
    "liabilitiesarisingfromfinancingactivities": 81286000,
    "netpaymentsoftransactioncostsfromborrowings": 2015000,
    "increasedecreaseinliabilitiesarisingfromfinancingactivities": 41557000,
    "amortizationoftransactioncostsclassifiedasnoncashfinancingactivities": 8417000,
    "financialassetsatfairvalue": 2317000,
    "financialliabilitiesatfairvalue": 47534000,
    "contingentconsiderationprovision": 47534000,
    "contingentconsiderationprovisionamountused": 800000,
    "gainlossonremeasurementofcontingentconsiderationprovision": 6300000,
    "descriptionofvaluationtechniquesusedinfairvaluemeasurementliabilities": "Discounted cash flows",
    "descriptionofinputsusedinfairvaluemeasurementliabilities": "Expected salesvolumes",
    "weightedaveragecostofcapitalsignificantunobservableinputsliabilities": 0.13,
    "descriptionofinterrelationshipsbetweenunobservableinputsandofhowtheymightmagnifyormitigateeffectofchangesinunobservableinputsonfairvaluemeasurementliabilities": "Year ended June 30, 2019: A 10% increase/decrease in sales volume assumptions adopted would increase/decrease the fair value by 4%.Year ended June 30, 2018: A 10% increase/decrease in sales volume assumptions adopted would increase/decrease the fair value by 4%.",
    "cashorstockpayableatfairvalueliabilities": 28005000,
    "royaltypaymentsatfairvalueliabilities": 19529000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 323000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": -17000,
    "disposalspropertyplantandequipment": 2000,
    "depreciationmethodpropertyplantandequipment": "Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over the estimated useful lives.",
    "usefullivesordepreciationratespropertyplantandequipment": "3 – 4 years",
    "usefullivesoramortisationratesintangibleassetsotherthangoodwill": "15 – 20 years",
    "numberofreportableoperatingsegment": 1,
    "posttaxdiscountrates": 0.155,
    "currentprovisionsforaccruedannualleave": 700000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 100000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsandgoodwill": -3000,
    "amortisationintangibleassetsotherthangoodwill": 1577000,
    "provisions": 55593000,
    "deferredtaxassetsattributabletotemporarydifferencesfromtaxlosses": 61742000,
    "deferredtaxassetsattributabletoothertemporarydifferences": 3687000,
    "deferredtaxassets": 65429000,
    "deferredtaxliabilitiesattributabletotemporarydifferencesfromintangibleassets": 76553000,
    "deferredtaxliabilities": 76553000,
    "deferredtaxassetsexpectedtobesettledaftertwelvemonths": 65429000,
    "deferredtaxliabilitiesexpectedtobesettledwithintwelvemonths": 99000,
    "deferredtaxliabilitiesexpectedtobesettledaftertwelvemonths": 76454000,
    "deferredtaxliabilityasset": 11124000,
    "netmovementinregulatorydeferralaccountbalancesrelatedtoprofitorlossandnetmovementinrelateddeferredtax": -8955000,
    "numberofsharesissued": 498626208,
    "treasurysharespurchased": 3500000,
    "numberofsharesoutstanding": 495126208,
    "ordinarysharespurchasedvalue": 910405000,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 212000,
    "sharebasedcompensationforservicesrenderedshares": 1209187,
    "sharesavailableforissuanceunderissuanceplan": 14464259,
    "issued": 15986554,
    "sharesissuedinplacementsvalue": 20000000,
    "shareissuerelatedcost": 817000,
    "contributionsofvalueforequityduringperiod": 20611000,
    "contributionsofequityduringperiod": 15986554,
    "shareoptionsreservetransferredtoequityonexerciseofoptionsvalue": 313000,
    "saleofequitypricepershare": 1.86,
    "premiumpercentageusedtocalculateequitypurchasepricepershare": 0.2,
    "valueofshareoptionsexercisedinsharebasedpaymentarrangement": -313000,
    "gainslossesonexchangedifferencesontranslationnetoftax": -137000,
    "adjustmentsfordepreciationandamortisationexpense": 2139000,
    "adjustmentsforunrealisedforeignexchangelossesgains": -154000,
    "adjustmentsforfinanceincomecost": -6914000,
    "remeasurementofborrowingarrangementsnet": 376000,
    "fairvalueremeasurementofcontingentconsiderationaftertax": 6264000,
    "adjustmentsforservicesrenderedinshares": 620000,
    "adjustmentsforsharebasedpayments": 4368000,
    "adjustmentsfordeferredtaxexpense": -8955000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 4974000,
    "adjustmentsforincreasedecreaseinprepayments": 5237000,
    "adjustmentsfordecreaseincreaseintaxassets": 1729000,
    "adjustmentsforincreasedecreaseintradecreditorsandaccruals": -3972000,
    "adjustmentsforprovisions": 2469000,
    "adjustmentsforincreasedecreaseindeferredconsideration": 10000000,
    "percentageofcashheld": 0.03,
    "changeininterestrateeffectonprofitloss": 0.05,
    "effectonprofitfromchangeintaxrate": 0.1,
    "noninterestbearingfinancialliabilitiesmaturityperiod": "P6M",
    "percentageofforecastnetsales": 0.2,
    "increasenoncurrentborrowing": 3500000,
    "decreaseinprofit": 3500000,
    "decreasenoncurrentborrowings": 1600000,
    "increaseinprofit": 1600000,
    "percentageofdecreasenetsales": 0.2,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -70000,
    "noncurrentfinancialliabilities": 50000000,
    "borrowingsadjustmenttointerestratebasis": 0.6,
    "currentfinancialliabilities": 48226000,
    "borrowingsinterestratepercentage": 0.1045,
    "increaseininterestratepercentage": 0.0245,
    "decreaseininterestratepercentage": 0.0201,
    "effectofincreaseininterestratechangeofborrowingsonprofit": 261000,
    "effectofdecreaseininterestratechangeofborrowingsonprofit": 261000,
    "fundsinvestedpercentage": 0.0223,
    "fundsinvestedwhichderivesinterestrevenue": 600000,
    "increaseininterestrateonfundsinvestedwhichderivesinterestrevenue": 1000,
    "decreaseininterestrateonfundsinvestedwhichderivesinterestrevenue": 1000,
    "percentageofpriceratechangesinborrowings": 0.4,
    "receivablesfromotherparties": 1740000,
    "receivablesfromincometax": 71000,
    "receivablefromforeignwithholdingtax": 400000,
    "receivablesfrombankdeposits": 252000,
    "valueaddedtaxreceivables": 2000,
    "receivablefromtaxcredits": 1467000,
    "derivativefinancialliabilitiesundiscountedcashflows": -140997000,
    "grossloancommitments": -81286000,
    "nameofsubsidiary": "BeiCell Ltd",
    "countryofincorporationorresidenceofsubsidiary": "Cayman Islands",
    "proportionofownershipinterestsheldbynoncontrollinginterests": 1,
    "milestonepayment": 2200000,
    "minimumleasepaymentspayableundernoncancellableoperatinglease": 1256000,
    "commitments": 1256000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 2723902,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 12074,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 45878,
    "keymanagementpersonnelcompensationsharebasedpayment": 297423,
    "keymanagementpersonnelcompensation": 3079277,
    "dateofgrantofsharebasedpaymentarrangement": "19/01/2019",
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "Options issued to employees generally vest based on service or time conditions. In the year ended June 30, 2019, senior executives were issued options that vest based on performance conditions. For time based vesting options, the first tranche typically vests 12 months after grant date, the second tranche 24 months after grant date, and the third tranche 36 months after grant date.",
    "percentageofpremiumattachedwithtimebasedvestingconditionoptions": 0.1,
    "employeeshareoptionplanmaximumnumberofoptionsavailableforissuance": 10000000,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement": 2.06,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsandloanfunded": "P4Y6M10D",
    "numberoftranchesofshareplangranted": 1,
    "expirytermofoptions": "P7Y",
    "tranchevestingterm": "P3Y",
    "optionexerciseterminconnectionwithcessationofemployment": "P60D",
    "optionsconversionratio": 63.978,
    "optionsvestedonacquisitiondate": "2010-12-07",
    "numberofequaltranchesvestondate": 3,
    "numberofequaltranchesvestingonachievementofmilestones": 2,
    "exercisepriceofoutstandingshareoptions": 1.45,
    "weightedaveragesharepriceshareoptionsgranted": 0.95,
    "closingsharemarketpriceofordinaryshare": 1.48,
    "sharebasedpaymentsarrangementexpirationdate": "18/01/2026",
    "numberofoutstandingshareoptions": 27737893,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 2985000,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 5693333,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 15572059,
    "weightedaverageshareprice": 2.06,
    "weightedaverageexercisepriceofshareoptionsinsharebasedpaymentarrangementexercisedduringperiodatdateofexercise": 1.16,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement": 4.58,
    "weightedaveragesharepriceexercisableinsharebasedpaymentarrangement": 2.35,
    "financialyearsofgrant": 2019,
    "exerciseorloanpershare": 1.45,
    "sharepriceatacceptancedate": 1.33,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.5395,
    "expectedlifeafterfactoring": "P5Y9M18D",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0119,
    "auditorsremunerationforauditservices": 89038,
    "auditorsremuneration": 779283,
    "basicearningslosspershare": -0.1816,
    "dilutedearningslosspershare": -0.1816,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententity": -89799000,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -89799000,
    "profitlossattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -89799000,
    "weightedaverageshares": 494381490,
    "adjustedweightedaverageshares": 494381490,
    "reserveofexchangedifferencesontranslation": -209207000,
    "reserveofsharebasedpayments": 65379000,
    "numberofoperatingsegment": 1,
    "receiptonnonrefundableupfrontpayment": 10000000,
    "revenuefromroyalties": 5000000,
    "descriptionofeligibilityonrefundabletaxoffset": "A refundable tax offset is available to eligible companies with an annual aggregate turnover of less than A$20.0 million. Eligible companies can receive a refundable tax offset for a percentage of their research and development spending. For the years ended June 30, 2019 and 2018, the rate of the refundable tax offset is 43.5%.",
    "annualaggregateturnoveramount": 20000000,
    "percentageofresearchanddevelopmenttoreceiverefundabletaxoffset": 0.435,
    "tradeandotherreceivablesdueforsettlementterm": "P60D",
    "tradeandotherpayablesmaturityperiod": "P60D"
  }
]